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CHAPTER I  
 
INTRODUCTION 
 
Inflammation 
 Inflammation is an organism’s protective response to an external chemical insult, physical injury, 
or harmful pathogen. When healthy tissue is damaged, there is an influx of immune cells that are transported 
from the blood to the site of injury. These cells include neutrophils, followed by monocytes, which can then 
differentiate into macrophages (1). With the increased presence of inflammatory leukocytes, various 
chemical species are released that are intended to eliminate the initial cause of injury from the affected site, 
clear any damaged tissue, and initiate the repair process. This acute phase of inflammation is characterized 
by five cardinal signs including pain, heat, redness, swelling, and loss of function (2). Typically, acute 
inflammation lasts for a few days, and the affected site of injury is successfully repaired by the controlled 
clearance of activated inflammatory cells and damaged tissue. However, if resolution is not achieved, 
inflammation can often last for extended periods of time, evolving to a chronic state. The loss of function 
of tissues in the affected area can often lead to organ failure and a plethora of diseases including 
neurodegeneration, cardiovascular diseases, inflammatory arthritis, cancer, and many others (3). Activated 
macrophages and neutrophils in an inflammatory site release a host of reactive oxygen and nitrogen species 
that serve to initiate a “chemical warfare” against the noxious pathogen. Many of these powerful chemical 
oxidants can also react with cellular macromolecules and modify their functions. Among the cellular 
components most prone to chemically react with these strong oxidant species are polyunsaturated fatty 
acids (PUFAs). These unsaturated carbon chains in the membrane bilayer of cells are susceptible to non-
enzymatic oxidation due to the presence of bis-allylic hydrogen atoms (4). PUFAs can also be liberated 
from phospholipids in the membrane bilayer and enzymatically converted to various oxygenated bioactive 
lipid compounds that contribute to the pathology, or in some cases, the resolution of inflammation.  
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Eicosanoids 
 
 One particular class of bioactive lipid molecules, the eicosanoids, is derived from arachidonic acid, 
an omega-6 fatty acid containing 20 carbons and 4 unsaturated carbon-carbon double bonds (w-6, 20:4) 
(AA) (Figure 1), or related 20-carbon PUFAs (5). AA is biosynthesized from the essential fatty acid linoleic 
acid (w6, 18:2) (LA), which is supplied from the diet (6). AA is then incorporated into the phospholipid 
bilayer by fatty acyl-CoA synthetase and lysophospholipid acyltransferase (7). In the membrane bilayer, 
AA is esterified at the sn-2 position of the glycerol moiety of individual phospholipids, including 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylinositol (PI) (8). To release 
AA from the bilayer, the enzyme phospholipase A2 (PLA2) hydrolyzes the acyl group at the sn-2 position. 
Among the three major classes of phospholipases, the calcium-dependent cytosolic PLA2 (cPLA2) is 
abundantly expressed in many cells and plays a major role in liberation of AA from the membrane bilayer 
(9). Once hydrolyzed, free AA is metabolized enzymatically, forming various classes of eicosanoids. 
Perhaps the most well-studied class is known as the prostanoids, consisting of prostaglandins (PGs) and 
thromboxane (TX), formed via the cyclooxygenase (COX) pathway (10). Another family of enzymes, the 
cytochromes P450 (P450s), convert AA to various lipids including hydroxyeicosatetraenoic acids (HETEs) 
and epoxyeicosatrienoic acids (EETs) (11). Additional eicosanoids including leukotrienes (LTs), lipoxins 
(LXs), and eoxins (EXs) are produced from the lipoxygenase (LOX) enzyme family (12). The focus of this 
work involves PG synthesis in the COX pathway, but the P450 and LOX pathways will briefly be discussed. 
 
 
Figure 1. Chemical structure of arachidonic acid, the precursor for various bioactive eicosanoids. 
 
 
 
 
 
O
OH
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Cytochromes P450 Pathway 
 
 P450s are heme-containing enzymes that oxidize xenobiotic toxicants, clinically used drugs, and 
carcinogens (13). P450s are expressed in the liver as well as various tissues throughout the body and 
catalyze a wide range of reactions, including the epoxygenation of AA. Currently, there are 18 mammalian 
P450 families, encoding 57 genes in the human genome (14). Members of the 2C and 2J families of P450s 
add one molecule of oxygen to AA to form an epoxide at one of each of the four double bonds of the 
substrate, producing various EETs. Furthermore, the 4A and 4F families of CYP450s can hydroxylate the 
terminal carbon of AA, producing 20-HETE (15). EETs function as autocrine or paracrine signaling 
molecules in the cardiovascular system where they produce vasorelaxation, and down-regulate several pro-
inflammatory signaling pathways (16). The terminally hydroxylated HETEs also exhibit anti-inflammatory 
effects by inhibiting the biosynthesis of LTs (17). EETs display rather short half lives in the cell, as they 
are hydrolyzed by epoxide hydrolases, producing dihydroxyeicosatrienoic acids (DHETs) (Figure 2). The 
enzyme primarily responsible for this reaction is soluble epoxide hydrolase (sEH). In contrast to the anti-
inflammatory properties observed for EETs, their corresponding diols are thought to be pro-inflammatory 
or biologically inactive (5).  
 
Figure 2. Cytochromes P450 enzymatic pathway. AA can be hydroxylated at its terminal carbon to form 
20-HETE. Alternatively, it can be epoxygenated to form regio- and stereo-specific epoxyeicosatrienoic 
acids (EETs), which are then hydrolyzed by epoxide hydrolases to form dihydroxyeicosatrienoic acids 
(DHETs). 
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Lipoxygenase Pathway 
LOXs are non-heme, iron-containing dioxygenases that metabolize AA and other PUFAs to potent 
signaling molecules involved in acute and chronic inflammatory processes such as allergy and asthma (18). 
The LOX enzymes initiate catalysis by abstracting a hydrogen atom from a bis-allylic carbon of the 
substrate PUFA. Carbon-carbon double bond resonance and subsequent oxygen addition produces a peroxyl 
radical, which is then enzymatically reduced to its corresponding hydroperoxide then to an alcohol, 
resulting in the regioselective and stereospecific addition of a hydroxyl group to a carbon on the PUFA 
(19). Various LOX isoforms have been studied, and each is named for the position of the carbon atom 
within AA to which molecular oxygen is added. In humans, six LOXs exist including 5-LOX, 12-LOX, 
12R-LOX, 15-LOX, 15-LOX-2, and eLOX3 (20). 
5-LOX, one of the most well-studied of the LOXs, has become a therapeutic target for anti-
inflammatory drugs.  5-LOX catalyzes the first step in the biosynthesis of LTs, which are potent signaling 
compounds involved in allergic inflammation, atherosclerosis, and disorders of the respiratory system (21). 
The production of LTs results from a two-step conversion of AA by 5-LOX. Upon stimulation by pro-
inflammatory signals, 5-LOX translocates to the nuclear membrane following the mobilization of 
intracellular calcium. Concurrently, AA is hydrolyzed from the membrane bilayer by cPLA2. Another 
membrane-bound protein, 5-LOX-activating protein (FLAP) is thought to act as a membrane scaffold for 
5-LOX, enabling it to anchor to the membrane. FLAP also is thought to deliver AA to the 5-LOX active 
site, although the biochemical mechanism by which this occurs is still not fully understood (22). The first 
step of 5-LOX catalysis involves the oxidation of AA to 5-hydroperoxyeicosatetraenoic acid (5-HPETE), 
an unstable intermediate. 5-HPETE is then enzymatically reduced to its corresponding alcohol (5-HETE) 
or epoxidized to form the lipid epoxide LTA4 (23). LTA4 can be subsequently hydrolyzed by the enzyme 
LTA4 hydrolase (LTA4H), forming LTB4, or conjugated with glutathione (GSH) to form the cysteinyl-
leukotriene, LTC4 by the enzyme LTC4 synthase (LTC4S) (24) (Figure 3). Successive hydrolysis of LTC4 
yields LTD4 and LTE4, potent mediators that reduce airflow to the alveoli and induce asthma (25). Various 
drugs have been developed to treat the allergic response and inflammatory disorders associated with the 
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increased presence of LTs, including zileuton (Zyflo), a 5-LOX inhibitor, and montelukast (Singulair), a 
cysteinyl LT receptor agonist (26,27). Furthermore, various inhibitors of FLAP have been developed to 
inhibit the biosynthesis of LTs. Currently, some inhibitors have been tested in clinical trials, but none has 
reached the market (28). 
 
Figure 3. Lipoxygenase enzymatic pathway. AA is oxygenated by 5-LOX in the presence of FLAP. The 
intermediate is then converted to LTA4. Hydrolysis of LTA4 by LTA4H yields LTB4. Alternatively, LTC4S 
can conjugate glutathione to LTA4, forming LTC4. 
 
 
Cyclooxygenase Pathway 
 In addition to the P450 and LOX biochemical pathways, AA and other PUFAs can be oxygenated 
by the COX enzymes. Initially, PG endoperoxides are produced, which can then be converted to PGs, 
including PGD2, PGE2, and PGF2a, PGI2 (prostacyclin), or TXA2 by downstream prostanoid synthases 
(Figure 4). 
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Figure 4. The Cyclooxygenase enzymatic pathway. AA is oxygenated to PGG2, which is then reduced to 
PGH2 by the COX enzymes. PGH2 is a substrate for various prostanoid synthases, producing PGs, 
prostacyclin (PGI2), and thromboxane. 
 
There are two isoforms of COX, designated COX-1 and COX-2. COX-1 is constitutively expressed in most 
tissues and maintains homeostatic levels of PGs, which are crucial for normal cardiovascular and 
gastrointestinal functions. The expression of COX-2, however, is induced in the presence of various pro-
inflammatory mediators such as cytokines, growth factors, and tumor promoters (29). Although their 
expression patterns differ, COX-1 and COX-2 enzymes share 60% sequence identity, and their three-
dimensional structures are nearly superimposable (30). Since COX-1 and COX-2 both produce pro-
inflammatory PGs, their inhibition has long been investigated through the development of nonsteroidal anti-
inflammatory drugs (NSAIDs) including indomethacin, ibuprofen, and aspirin for the treatment of pain, 
fever, and inflammation (31). Since the expression of COX-2 is associated with the inflammatory response, 
various drugs were developed to selectively target its inhibition, while maintaining the normal physiological 
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function of COX-1. These COX-2-selective inhibitors (coxibs) were hypothesized to exploit the anti-
inflammatory effects of traditional NSAIDs with fewer side effects. Coxibs such as celecoxib (Celebrex), 
rofecoxib (Vioxx), and valdecoxib (Bextra) displayed efficacious anti-inflammatory properties and 
decreased gastrointestinal toxicity. However, chronic use of coxibs in clinical trials of cancer prevention 
resulted in increased cardiovascular toxicity and the subsequent removal of all drugs of this class with the 
exception of celecoxib from the U.S. market (32). 
 
Cyclooxygenase Mechanism 
 The formation of PGs from AA was initially studied using cellular homogenates of ram seminal 
vesicles. The experiments showed that the radiolabeled AA was converted to radiolabeled PGE2, thus 
indicating fatty acids as biological precursors of PGs (33,34). Additional experiments using stereospecific, 
isotopically labeled fatty acid substrates indicated that the oxygenation is initiated by removal of the pro-S 
allylic hydrogen from carbon-13 of AA (35). From these studies, it was proposed that a free radical 
mechanism enables the oxygenation of AA to the hydroperoxy-endoperoxide intermediate PGG2 followed 
by reduction of the hydroperoxyl group of PGG2 by COX to yield PGH2 (Figure 5). Thus, the enzyme 
catalyzes both a cyclooxygenase (COX) reaction, yielding PGG2 and a peroxidase (POX) reaction to 
produce PGH2. The two reactions occur at distinct active sites, both of which are dependent on heme. 
 Following their expression in cells, the COX enzymes are structurally mature hemoproteins, but 
must first be activated by a hydroperoxide. To initiate catalysis, a two-electron reduction of the 
hydroperoxide substrate at the peroxidase active site oxidizes the ferric heme to an oxo-ferryl porphyrin 
cation radical. Since hydroperoxide activation is required to initiate COX catalysis, the enzyme exhibits a 
lag phase which complicates kinetic analysis in vitro (36). The COX enzyme also experiences self-
inactivation before all substrate is consumed, with the process beginning instantaneously and in a 
concentration- and time-dependent manner (37). The mechanism of COX self-inactivation is not completely 
understood but could be due to covalent modification of the enzyme from substrate metabolism (38). The 
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identities of the initial hydroperoxide activator and reducing co-substrate in vivo are not known, but 
evidence suggests peroxynitrite could serve such a role (39). 
 The oxidized heme cation radical in the POX active site is subsequently reduced by a single electron 
from Tyr-385, reducing it back to a fully covalent oxy-ferryl protoporphyrin. The oxy-ferryl heme can 
further be reduced by an electron from a reducing co-substrate to its resting ferric state. The tyrosyl radical 
generated from Tyr-385 oxidation is close to the pro-S hydrogen of carbon-13 of AA bound in the 
cyclooxygenase active site. Abstraction of this hydrogen generates a radical on carbon-11, initiating the 
cyclooxygenase reaction. The carbon-centered radical reacts with molecular oxygen, forming an 11 (R)-
hydroperoxyl radical. The radical then reacts with carbon-9, generating a cyclic endoperoxide with 
migration of the radical to carbon-8. This radical will then add to carbon-12, forming a new carbon-carbon 
bond. Eventually, the radical resonates to carbon-15 and reacts with a second molecule of oxygen, forming 
a hydroperoxyl radical which abstracts the hydrogen atom from Tyr-385 to yield the intermediate PGG2. 
The final step of the catalytic mechanism involves the reduction of the 15-hydroperoxide of PGG2 to its 
corresponding alcohol, forming the final PGH2 product (40). The regenerated tyrosyl radical can continue 
multiple substrate turnovers without additional peroxide activation.  
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Figure 5. Cyclooxygenase catalytic mechanism. The activation of the enzyme by a hydroperoxide oxidizes 
the heme prosthetic group in the peroxidase site which can then oxidize Tyr-385, generating a tyrosyl 
radical. The abstraction of the 13-pro-(S)-hydrogen of AA by the tyrosyl radical initiates the branched chain 
radical mechanism in the cyclooxygenase active site. The reduction of the peroxyl radical to form PGG2 
regenerates the tyrosyl radical for multiple substrate turnovers. Reprinted from Curr Opin Chem Biol., 4(5), 
Marnett, L.J., Cyclooxygenase mechanisms, 545-552, Copyright 2000, with permission from Elsevier (41). 
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Cyclooxygenase Structure  
 
 Based on immunoelectron microscopy with antibodies specific to each isoform of the COXs, it was 
discovered that both COX-1 and COX-2 are found on the lumenal surfaces of the endoplasmic reticulum 
(ER) as well as the inner and outer membranes of the nuclear envelope (42). The COX enzymes are 
homodimers, with COX-1 and COX-2 containing 576 and 581 amino acid residues, respectively, following 
the cleavage of their N-terminal signal peptides in the ER. Each monomer of approximately 70 kDa contains 
three distinct domains. Residues 34-72 make up the epidermal growth factor (EGF)-like domain, the 
function of which is still not fully understood, but most likely stabilizes the catalytic domain of the enzyme 
through disulfide bond formation. Residues 73-116 serve as a membrane binding domain (MBD), enabling 
the enzyme to anchor into the hydrophobic lipid bilayer. The remaining bulk of the enzyme consists of the 
catalytic domain, consisting of the two separate COX and POX active sites, which are separated by the 
heme prosthetic group (43) (Figure 6A). One heme per COX dimer is sufficient for full catalytic activity, 
suggesting half-of-sites reactivity (44). The POX site allows sufficient solvent accessibility to the heme to 
accommodate large alkyl peroxides such as PGG2 and 15-HPETE. These peroxides have a higher affinity 
for the POX site and are reduced more efficiently than smaller peroxides such as hydrogen peroxide (45). 
The COX active site, which lies between the heme of the peroxidase site and the MBD, consists of a 
hydrophobic channel bent in an L-shaped conformation. The channel originates with a large “lobby” region 
in the MBD that is demarcated by a constriction formed by three residues, Arg-120, Tyr-355, and Glu-524. 
These residues form a constriction that must open to allow the entrance of substrates and inhibitors, into 
the upper portion of the active site (46). Above the constriction, the active site consists of a central channel 
that forms a near-right angle bend at Ser-530. This critical location of Ser-530 explains why its acetylation 
by aspirin inhibits PGG2 formation. AA binds in this channel with the carboxyl group in close proximity to 
Arg-120 and Tyr-355 at the constriction site, carbon-13 aligned with the catalytic Tyr-385, and the w-tail 
deep in the alcove above Ser-530. Tyr-385 is in favorable position to abstract the allylic hydrogen from 
carbon-13 when AA binds in the active site (Figure 6B). Beyond Tyr-385 and Ser-530, the w-tail of AA 
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extends into a hydrophobic upper channel that lies between helices 2 and 17 consisting of residues Phe-
205, Phe-209, Phe-210, Val-228, Ile-341, Val-344, Ile-377, Phe-381, and Leu-534 (10). The COX active 
site terminates at Gly-533. The mutation of Gly-533 to larger hydrophobic residues will not allow for the 
oxygenation of AA but will allow COX to oxygenate shorter chain fatty acids (46). 
 
Figure 6. COX-2 enzyme structure. (A) The catalytic domains of each monomer, colored in red and blue, 
form noncovalent interactions at the dimer interface, playing a role in the allostery of the enzyme’s activity. 
The membrane binding domains of both monomers, colored in yellow, anchor the enzyme to the lipid 
bilayer of the ER lumen. The EGF domain is colored in green. (B) AA in the active site of COX-2 along 
with residues at the constriction site, Ser-530 at the channel bend, and the catalytic Tyr-385 in close 
proximity to carbon-13 of AA (yellow). Figures generated from PDB entries 4Z0L and 3KRK (47,48). 
 
Cyclooxygenase Isoform Differences 
 The formation of PGs from COX-1 is proposed to maintain homeostatic biological functions, 
whereas the expression of COX-2 and concomitant increase in PG production is associated with an 
inflammatory or tumorigenic state. Other differences distinguish the isoforms of COX from one another in 
regard to various biochemical properties. Although both COX-1 and COX-2 oxygenate AA with similar 
catalytic parameters, COX-2 has been shown to be more sensitive to peroxide activation than COX-1. An 
approximately 10-fold lower concentration of hydroperoxide is necessary to initiate COX-2 than COX-1 
activity, thus explaining the difference in their relative activities in cells with varying peroxide 
concentrations (49). One of the major biochemical differences between COX-1 and COX-2 is the size of 
their cyclooxygenase active sites. COX-2 contains a side pocket, consisting of residues Val-434, Arg-513, 
and Val-523. The corresponding residues in COX-1 are Ile-434, His-513, and Ile-523, thus making its active 
Tyr-385
Ser-530
Tyr-355
Glu-524 Arg-120
A B
 12 
site approximately 24% smaller than that of COX-2 (50). The larger volume of the COX-2 active site was 
exploited for the development of selective COX-2 inhibitors (51). Additional structural differences between 
the COX isoforms differentiates their ability to oxygenate particular substrates. Arg-120 in COX-1 is 
critical for binding of AA, but not necessarily for COX-2. If this residue is mutated to Gln in COX-1, the 
Km for AA increases 1000-fold, but the same mutation in COX-2 does not alter the Km or Vmax for AA (52).  
Therefore, COX-2 can oxygenate neutral amide and ester derivatives of AA with much higher catalytic 
efficiency than COX-1. Some of these substrates include the endocannabinoids 2-archidonoylglycerol (2-
AG) and arachidonoylethanolamide (AEA) (53) (Figure 7). In fact, human and mouse COX-2 oxygenate 
2-AG with a comparable catalytic efficiency (54) (Table 1). Both 2-AG and AEA are endogenous agonists 
for the CB1 and CB2 receptors which are also modulated by D9- tetrahydrocannabinol (THC), the 
psychoactive compound of the cannabis plant (55,56). COX-2 has also been shown to oxygenate additional 
amide substrates that COX-1 cannot. One such substrate is the lipoamino acid N-arachidonylglycine 
(NAGly), which possesses analgesic effects and suppresses inflammatory pain (57). COX-1 and COX-2 
also differ in their ability to oxygenate other fatty acids with varying degrees of chain length and saturation 
including linoleic acid, g-linolenic acid (g-LNA), and a-linoleic acid (58). One last difference between the 
COX isoforms is product formation following covalent acetylation by aspirin. The acetylation of Ser-530 
of COX-1 completely inhibits substrate oxygenation. However, aspirin-mediated acetylation of COX-2 still 
allows the oxygenation of AA to form 15-HETE and 11-HETE, essentially transforming the enzyme to a 
lipoxygenase (59).  
 
 
Figure 7. Additional COX-2 substrates, the endocannabinoids 2-AG and AEA. COX-2 oxygenates these 
substrates to prostaglandin glyceryl esters (PGGs) and prostaglandin ethanolamides (prostamides). 
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Table 1. Steady-state kinetic parameters for COX-2 isoforms in the presence of various substrates. Table 
was generated from from Biochem Biophys Res Commun., 338(1), Rouzer, C.A. and Marnett, L.J., 
Structural and functional differences between cyclooxygenases: fatty acid oxygenases with a critical role 
in cell signaling, 34-44, Copyright (2005), with permission from Elsevier (60). 
 
 kcat (s-1) KM (µM) kcat/KM (s-1 µM-1) 
Human COX-2    
AA 15 ± 1 6.1 ± 0.6 2.4 
2-AG 17 ± 1 4.4 ± 0.9 4.0 
Murine COX-2    
AA 21 ± 2 8.2 ± 1.6 2.5 
2-AG 11 ± 1 4.7 ± 0.8 2.3 
AEA 0.1 24 0.0042 
NAGly 6.3 ± 1.1 12 ± 1 0.54 
 
Cyclooxygenase Functions as a Heterodimer 
 Each subunit of the COX enzyme dimer is structurally identical to the other with which it forms a 
series of non-covalent interactions at the dimer interface. Despite this structural identity, the monomers 
exhibit varying affinities for binding heme (44). The COX dimer binds one heme cofactor with high affinity 
in one monomer, which acts as the catalytic subunit. The opposite monomer binds heme with much lower 
affinity, and substantial data suggest that it allosterically regulates the activity of the catalytic monomer. 
Therefore, current kinetic and mutagenic data suggest that the enzyme functions as a heterodimeric enzyme 
(61). For example, COX-2 heterodimers that were expressed and purified with one native subunit and one 
subunit with a Y385F mutation displayed similar kinetic parameters as the COX-2 heterodimer with two 
native subunits. In fact, the heme cofactor was shown to bind with even higher affinity to the native subunit 
in the presence of the Y385F mutant subunit (62). Substrate oxygenation in the catalytic subunit of the 
COX heterodimer is modulated by occupancy of various compounds in the allosteric subunit. Many 
nonsubstrate fatty acids preferentially bind to the allosteric subunit and can stimulate the oxygenation of 
AA. Specifically, palmitic acid (PA) is an efficacious activator of the enzyme, increasing the catalytic 
conversion of AA to PGH2 by approximately 80% (61). In other instances, nonsubstrate fatty acids can 
 14 
significantly affect the oxygenation of a particular substrate. An example is the potentiation of 2-AG 
oxygenation by the nonsubstrate AA derivative, AM-8138 (13(S)-methylarachidonic acid). Upon binding 
in the COX-2 allosteric site, 2-AG oxygenation is increased approximately 3.5-fold, whereas AA 
oxygenation is unchanged (63). In addition to nonsubstrate molecules, COX substrates exert allosteric 
regulation of one another. Mitchener, et al. demonstrated that AA inhibits 2-AG oxygenation in a 
concentration-dependent manner, whereas 2-AG mildly stimulates AA oxygenation. This complex 
interplay between the COX substrates using a kinetic modeling system demonstrated that competition of 
AA and 2-AG substrates in both allosteric and catalytic subunits ultimately results in a preferential 
oxygenation of AA (64).  
Despite the presence of over 70 X-ray crystal structures of COX-1 or COX-2 in complex with 
various substrates or inhibitors in the Protein Data Bank (PDB), the basis for the interaction between the 
catalytic and allosteric subunits of COX is still not fully understood. In nearly all crystal structures, both 
monomers of the enzyme are fully occupied with substrate or inhibitor, even when crystallized with sub-
stoichiometric amounts of ligand. Therefore, the enzyme preferentially crystallizes in a fully occupied form. 
Furthermore, few structural differences are noted either in the active site or at the dimer interface between 
liganded and apo-enzyme (65).  In one experiment, COX-1 was crystallized with various NSAIDs and 
changes were observed in the occupancy of particular amino acid residues in a partially occupied subunit. 
In cases where one monomer of the enzyme was bound to an inhibitor and the other monomer was 
incompletely occupied, a loop region at the dimer interface consisting of residues 123-129 was observed in 
an alternate conformation. Based on this structural variation as well as previous cross-linking experiments 
demonstrate that this loop region could be involved in monomer cross-talk and could potentially affect 
interactions between each subunit (65). 
 
Molecular Basis of COX Inhibition  
 Numerous NSAIDs that nonselectively inhibit the activity of both COX-1 and COX-2 and coxibs 
that selectively inhibit COX-2 have been developed (66) (Figure 8). Inhibitors of the COX enzymes bind 
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in the COX active site in a noncovalent manner, with the exception of aspirin and 2-acetoxyphenylhept-2-
ynyl sulfide (APHS), which transfer an acetyl group to Ser-530, or selectively to COX-2, respectively 
(31,67,68). The time-dependence of COX inhibition by aspirin, first described in 1971, was discovered to 
be due to acetylation of the active site Ser-530 residue (69). Mutating Tyr-385 to Phe is detrimental to 
aspirin acetylation of COX (70), suggesting that this residue plays a role in the reaction. Data suggest that 
Tyr-385 acts as a hydrogen bond donor to aspirin’s acetyl group, thus stabilizing the tetrahedral 
intermediate formed during the reaction. Although aspirin acetylates both isoforms, it is between 10- and 
100-fold more potent for acetylating COX-1 than COX-2 (71).  
Most noncovalent NSAIDs and coxibs are generally classified as either rapidly reversible, 
competitive inhibitors or slow, tight-binding inhibitors. Rome and Lands described a kinetic model for 
time-dependent noncovalent COX inhibition using various inhibitors. Their data indicated that the kinetics 
of COX inhibition by the NSAIDs ibuprofen and mefenamic acid were consistent with the classical model 
of rapidly reversible competitive inhibition. In contrast, flurbiprofen and meclofenamic acid displayed time-
dependent inhibition that became functionally irreversible, indicative of a two-step binding mechanism 
consisting of an initial rapid, reversible binding step of the inhibitor to the enzyme, followed by an 
essentially irreversible, time-dependent formation of the inhibitor-enzyme complex (72). For this two-step 
binding, a kinetic model was developed, where the initial inhibitor enzyme complex binding is represented 
by a dissociation constant (KI), followed by the functionally irreversible tight-binding step represented by 
the rate constant kinact as seen in Equation 1: 
E + I 
𝑘"⇄𝑘$"[EI] 𝑘%&'()→  EI* KI = k-1/k1 (Equation 1) 
Following the initial kinetic description of COX inhibitor binding mechanisms, additional inhibitors were 
investigated, with most NSAIDs, like diclofenac and indomethacin, exhibiting a two-step binding 
mechanism (Equation 2): 
E + I 
𝑘"⇄𝑘$"[EI] 𝑘+⇄𝑘$+EI*  (Equation 2) 
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Or a three-step binding mechanism as observed for COX-2 selective diarylheterocycles such as celecoxib 
(Equation 3): 
E + I 
𝑘"⇄𝑘$"[EI] 𝑘+⇄𝑘$+[EI*] 𝑘-⇄𝑘$-EX  (Equation 3) 
 
 
 
Figure 8. Chemical structures of COX inhibitors. 
 
Like the AA substrate, many NSAIDs contain a carboxylic acid moiety that forms noncovalent polar 
interactions with the COX enzymes. Multiple crystal structures of enzyme-inhibitor complexes in addition 
to site-directed mutagenesis studies have given further insight into the molecular basis of COX inhibition. 
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Residues at the constriction site form noncovalent interactions with many NSAIDs, most commonly with 
the carboxylate ion pairing with Arg-120 and/or forming a hydrogen bond with Tyr-355. Some time-
dependent NSAIDs containing carboxylates like flurbiprofen and indomethacin form ion pairs with Arg-
120 in COX-1. This interaction is crucial for their inhibition as mutation of Arg-120 to Glu eliminates their 
inhibitor effects (73). In COX-2 however, the mutation of Arg-120 does not abolish inhibition by 
indomethacin. Additional studies utilizing a methyl ester analogue of indomethacin revealed that binding 
to COX-1 became time-independent and that the carboxylate was required for its tight binding to the 
enzyme (72). For COX-2 inhibition, the methyl ester of indomethacin does not eliminate its time-
dependence, but the inhibitor does bind to the enzyme with lower affinity (74,75). A crystal structure of 
COX-2 in complex with indomethacin shows that in addition to ion pairing to Arg-120, additional contacts 
are made with Tyr-355 at the constriction site, the chlorine atom interacts with Leu-384 at the top of the 
active site, and the 2´-methyl group projects into a hydrophobic pocket formed by the residues Val-349, 
Ala-527, Ser-530, and Leu-531 (51). A 2´-des-methyl analogue is a rapid, reversible inhibitor of COX-2 
and, to some extent, of COX-1 (76). However, substituting the 2´-methyl group to a larger trifluoromethyl 
group produces a tight-binding inhibitor that is selective for COX-2 inhibition (77). Therefore, binding of 
the 2´-methyl group of indomethacin in the hydrophobic pocket is a crucial property for its time-dependent 
inhibition of COX. Mutating Arg-120 to Gln also decreases the potency of indomethacin and the 
trifluoromethyl analogue, indicating that both ion-pairing and hydrogen bonding interactions are important 
for these inhibitors (77). 
 In addition to Arg-120, the hydroxyl group of Tyr-355 is in favorable binding distance to the 
carboxylate of some NSAIDs (78). Tyr-355 has been found to have a determinant role in the enantiospecific 
inhibition of AA oxygenation by COX in the presence of 2-propionic acid inhibitors like flurbiprofen and 
ibuprofen. The (S)-enantiomer of flurbiprofen exhibits potent inhibition of AA oxygenation in the presence 
of wild-type enzyme, but the (R)-enantiomer is a poor inhibitor. However, the (R)-enantiomer of 
flurbiprofen has similar IC50 values in the presence of wild-type enzyme and a Y355F mutant (79). The 
Y355F mutation also decreases the transition state energy of the slow-binding inhibition step for 
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flurbiprofen and indomethacin, thus indicating Tyr-355 is involved in the molecular mechanism of time-
dependent inhibition for these inhibitors (80). 
 Other carboxylate-containing NSAIDs display either one- or two-step binding mechanisms but 
bind in the COX active site in a different orientation. Like indomethacin, diclofenac is a slow, tight-binding 
inhibitor of COX. However, the mutation of either Arg-120 to Ala or Tyr-355 to Phe does not affect the 
inhibitory potency of diclofenac. The crystal structure shows that diclofenac binds in the COX active site 
in an “inverted” orientation (Figure 9). Its carboxylate makes no contacts with Arg-120 or Tyr-355, but it 
does form hydrogen bonds with Tyr-385 and Ser-530 (81). Mutating Ser-530 to Ala is detrimental to 
diclofenac inhibition (IC50 > 50 µM) and a Ser-530-Met mutation resulted in a 240-fold increase in the IC50 
value for diclofenac relative to that of the wild-type enzyme (82). The selective COX-2 inhibitor 
lumiracoxib is a rapid, reversible inhibitor of AA oxygenation that also binds in an inverted orientation with 
its carboxylate forming hydrogen bonds with Tyr-385 and Ser-530. Mutating Ser-530 to Ala abolishes 
sensitivity to lumiracoxib inhibition  (83). Lumiracoxib also contains a 5´-methyl group that clashes with 
the side chain of Leu-384 of COX-1, suggesting a mechanism for its selectivity of COX-2 inhibition over 
COX-1 (84). 
 
Figure 9. Crystal structure of diclofenac bound to active site of mCOX-2 (PDB: 1PXX). 
Tyr-385
Ser-530
Arg-120
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 Many of the coxibs designed to selectively inhibit COX-2 are of the diarylheterocycle class, 
consisting of inhibitors such as celecoxib, rofecoxib, valdecoxib, and etoricoxib. Celecoxib was evaluated 
for its ability to inhibit COX-1 and was found to exhibit competitive, reversible kinetics (85). For COX-2 
inhibition, an initial competitive interaction is observed, followed by a time-dependent mechanism, forming 
a tight enzyme-inhibitor complex. Upon further investigation, it was determined that celecoxib actually 
binds to COX-2 in a three-step mechanism, with the final two steps being kinetically distinct based on the 
magnitudes of their rate constants (86). In comparing the sequences of COX-1 and COX-2, the only 
difference within in the central channel of the COX-2 active site not conserved in COX-1 is a Val-523 
residue. If this residue is mutated to Ile in human COX-2, the coxibs lose their time-dependence of 
inhibition and the selectivity of the inhibitors for COX-2 is abolished, whereas NSAIDs like indomethacin 
show no difference in regard to their selectivity. The crystal structure of COX-2 in complex with a celecoxib 
analogue shows that its sulfonamide group binds in the side pocket of the active site next to Val-523. Thus, 
the insertion of the sulfonamide or methylsulfonyl groups of coxibs past Val-523 in the COX-2 active site 
dictates their time-dependent step for inhibition (51). 
 Time-dependence of COX-2 inhibition is also dependent on peripheral residues which are not part 
of the active site where NSAIDs bind. In COX-2, a Val-89 residue lies in a space in the lobby just outside 
of the active site, between helices B and D. Mutating this residue to a bulkier Trp residue reduced the size 
of the entrance into the active site from the lobby region. The mutation of adjacent His-90 residue to Trp 
further reduced the size of the entrance to a proposed alternative route for substrates and inhibitors to enter 
the active site. The increased steric bulk from these mutations transformed the kinetic behavior of rapid, 
reversible inhibitors of COX-2 such as ibuprofen and mefenamic acid into slow, tight-binding inhibitors. 
Single mutant studies and crystal structures indicated that Val-89 is the residue primarily responsible for 
the shift in inhibitor time-dependence and its mutation to a bulkier residue remodels the structure of the 
lobby route channel (87). 
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Substrate-selective Inhibition of COX 
Both the potency and the time-dependence of some COX inhibitors vary substantially depending 
on the substrate being utilized. The initial experiments describing COX inhibition by ibuprofen and 
mefenamic acid were based on the conversion of AA to PGs. Later experiments, however, revealed that 
these inhibitors display “substrate-selective” properties. Although both ibuprofen and mefenamic acid are 
weak, competitive inhibitors of AA oxygenation, they are potent, noncompetitive inhibitors of 
endocannabinoid oxygenation by COX-2. Based on these observations, it was proposed that binding of one 
molecule of each inhibitor in the allosteric subunit is sufficient to prevent the oxygenation of the 
endocannabinoid substrate in the catalytic subunit, thus preventing its oxygenation. However, a single 
inhibitor molecule in the allosteric subunit still allows AA oxygenation, and much higher concentrations of 
inhibitor are necessary to compete AA out of the catalytic site to prevent its oxygenation (88). This result 
thus reemphasizes the importance of the cross-talk between the monomers of the COX enzyme and the 
demonstrates how the presence of a compound in the allosteric subunit can affect the oxygenation of 
substrates in the catalytic subunit, especially for the endocannabinoids in the presence of COX-2.  
Additional experiments investigated the substrate-selectivity of weak, reversible inhibitors as well 
as slow, tight-binding inhibitors. A particular class of NSAIDs, the propionic acids, display 
enantiospecificity for inhibiting the oxygenation of AA by the COX enzymes. As noted above, the (S)-
enantiomers of these inhibitors including ibuprofen, flurbiprofen, and naproxen prevent the oxygenation of 
AA, but the (R)-enantiomers are poor inhibitors. With regard to 2-AG oxygenation, the weak, reversible 
inhibitors, including the (R)-propionic acids, are also potent inhibitors. Initial studies with site-directed 
mutagenesis and structure-activity relationships suggested that unfavorable binding of the (R)-propionic 
acids in the active site was due to steric clash between the inhibitor a-methyl group and Tyr-355 (79). 
However, the crystal structure of COX-2 and (R)-naproxen revealed that the constriction site residues that 
form interactions with the inhibitor, Arg-120 and Tyr-355, can reposition themselves to sterically 
accommodate the a-methyl group for favorable binding in the active site. Furthermore, Arg-120 is crucial 
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for binding of (R)-flurbiprofen to the enzyme, as mutation of Arg-120 to Gln eliminates inhibition (Figure 
10). Thus, the binding of the (R)-propionic acids in the allosteric subunit of COX-2 likely induces a 
conformational change in the catalytic site, preventing the oxygenation of endocannabinoids (89). 
 
Figure 10. Crystal structure of (R)-flurbiprofen in the COX-2 active site. Ion-pairing of the inhibitor with 
Arg-120 is critical for its binding. Reprinted from Nat Chem Biol., 7(11), Duggan, K., (R) Profens Are 
Substrate-Selective Inhibitors of Endocannabinoid Oxygenation by COX-2, 803-809, Copyright 2011, with 
permission from Nature America Inc. (89). 
 
 
In addition to mefenamic acid, other fenamic acid inhibitors have been tested for their ability to 
inhibit COX activity in a substrate-selective manner. These inhibitors, including flufenamic acid, 
meclofenamic acid, and tolfenamic acid, are structurally similar to phenyl acetic acid NSAIDs such as 
diclofenac and lumiracoxib. Unlike many NSAIDs, the fenamates are observed to bind in the COX active 
site in an inverted orientation with their carboxylic acid moieties forming interactions with Tyr-385 and 
Ser-530 (Figure 11). Based on this observation and spectroscopic studies, it was found that the fenamates 
can quench the radical formed at the catalytic tyrosine and reduce the heme cofactor back to its resting state, 
essentially resetting the enzyme and requiring additional turnover of peroxide to continue substrate 
oxygenation. Endocannabinoid oxygenation requires higher concentrations of peroxide in comparison to 
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AA oxygenation (90). Therefore, the substrate-selectivity of these inhibitors may be, at least in part, 
dependent on the peroxide tone associated with their interactions with the enzyme active site (91).  
 
Figure 11. Crystal structure of mefenamic acid in the COX-2 active site. The inhibitor binds in an inverted 
orientation relative to many other NSAIDs, with its carboxylate group forming interactions with Tyr-385 
and Ser-530. Figure generated from PDB 5IKR (91). 
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Prostaglandin Isomerization 
 As described above, COX oxygenation of AA produces the product PGH2. In vivo, PGH2 
spontaneously decomposes into the prostanoids PGD2 and PGE2 with a half-life of approximately 90 – 100 
seconds (92). PGH2 can also be enzymatically isomerized to various PGs, PGI2, and TXA2 by various 
synthases. These prostanoids exhibit various biochemical processes by binding to their respective G 
protein-coupled receptors (GPCRs). Here, we focus on one of the isomerases that produced PGE2. 
 
PGE Synthase 
 PGE2 is a PG consisting of a cyclopentane nucleus bearing a keto group at carbon-9 and a hydroxyl 
group at carbon-11. It is isomerized from PGH2 by three separate PGE synthases (Figure 12), including 
cytosolic PGE2 synthase (CPGES), microsomal PGE2 synthase-1 (mPGES-1), and microsomal PGE2 
synthase-2 (mPGES-2) (93).  
 
Figure 12. PGH2 isomerization to PGE2 by the PGE synthases. 
 
As a member of the cytosolic glutathione S-transferase (GST) superfamily of enzymes, CPGES is a 
glutathione-dependent enzyme that is also identical to p23, a heat-shock protein 90 (HSP90)-binding 
protein (94). The enzyme is expressed in a wide variety of cells and tissues and preferentially isomerizes 
PGH2 that is derived from COX-1. Therefore, CPGES is believed to be functionally coupled to COX-1 to 
maintain homeostatic production of PGE2 in cells (95). 
 mPGES-2 was initially determined to be a membrane-bound enzyme containing both heme and 
GSH in its active site, and it was believed to catalyze PGH2 degradation to 12L-hydroxy-5,8,10-
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heptadecatrienoic acid (12-HHT) (96). A subsequent study demonstrated that mPGES-2 isomerizes PGH2 
to PGE2. Furthermore, it was proposed that the enzyme was activated by a variety of compounds containing 
sulfhydryl groups in addition to GSH, including dihydrolipoic acid and dithiothreitol (DTT), and that heme 
was not involved in the enzymatic reaction (97). In order to clarify the role of heme, absorption and 
fluorescence experiments were utilized to investigate the heme association/dissociation with the enzyme. 
From these studies, it was determined that heme only binds to the enzyme in the presence of GSH. A low 
dissociation constant indicated that the heme binds tightly to the enzyme, but it can be dissociated by 
exposure to DTT, which produces heme-free enzyme that has the ability to isomerize PGH2 to PGE2 (98). 
mPGES-2 is constitutively expressed and isomerizes PGH2 derived from both COX-1 and COX-2, thus 
making its physiological relevance less well understood (99). 
 
mPGES-1 
MAPEG Proteins 
 mPGES-1 is a member of the membrane-associated proteins in eicosanoid and glutathione 
metabolism (MAPEG). This family of enzymes includes several nonmammalian members and six 
mammalian members that can be divided into four subgroups based on their sequence alignments. Group I 
contains microsomal GSH transferase (MGST) 2, FLAP, and LTC4S. Group II contains only MGST3. 
Group III contains bacterial MAPEG members, and finally, group IV consists of MGST1 and mPGES-1 
(100). Based on sequence alignments and hydropathy plots, it was predicted that the MAPEG proteins are 
composed of membrane-spanning helices (101). Initially, the structures of MGST1 and mPGES-1 were 
solved utilizing electron microscopy of two-dimensional crystals (102,103). Concurrently, X-ray crystal 
structures were obtained for LTC4S and FLAP (104,105). These structures revealed that the MAPEG 
proteins share similar characteristics; all are homotrimers of subunits that each comprise four 
transmembrane (TM) helices. Additionally, a molecule of GSH binds at the interface of adjacent subunits 
in each of the proteins with the exception of FLAP, which has not been shown to bind GSH (106).  
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 The MAPEG proteins carry out various biological processes, including the catalytic production of 
PGE2 and LTs, as well as the conjugation of GSH to various electrophiles for the purpose of excreting 
potentially toxic compounds. MGST1 can catalyze the nucleophilic substitution of GSH to the substrate 1-
chloro-2,4-dinitrobenzene (CDNB) with the formation of a thiolate anion being a rate-determining step in 
enzyme turnover (107). MGST1 can also catalyze the conjugation of GSH to LTA4 to form LTC4, the same 
enzymatic function as LTC4S (108). MGST2 has similar biochemical functions to those of MGST1, 
including the conjugation of GSH to electrophilic xenobiotics as well as to LTA4, although with reduced 
efficiency (109). MGST3 is unable to catalyze the conjugation of GSH to CDNB but can conjugate GSH 
to LTA4 to form LTC4. Furthermore, both MGST2 and MGST3 exhibit GSH-dependent peroxidase activity 
by reducing 5-HPETE to 5-HETE (110). FLAP is the only mammalian member of the MAPEG family that 
does not bind GSH and utilize it as cofactor. In fact, FLAP technically does not have any known enzymatic 
activity. It was discovered by observing that an inhibitor, MK-886, inhibited the synthesis of LTA4 in whole 
human leukocytes but not by purified 5-LOX (111). Eventually, the molecular target of a radio-labeled 
analogue of MK-886 was identified as FLAP, which is necessary for LT biosynthesis by 5-LOX in intact 
cells (112).  
 
mPGES-1 
 As noted above, mPGES-1 is MAPEG protein that is most closely related to MGST1, with 38% 
sequence identity (113). mPGES-1 is a GSH-dependent membrane-bound enzyme, and its expression is 
induced by pro-inflammatory cytokines and growth factors such as bacterial lipopolysaccharide (LPS), 
interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) (114). It is also co-localized with COX-2 in 
the perinuclear membrane and the ER. This coupled localization is associated with the induced production 
of PGE2 (115).  
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mPGES-1 Function 
 mPGES-1 catalyzes the isomerization of PGH2 to PGE2; the former is derived primarily from COX-
2. mPGES-1 can also utilize PGG2, the intermediate from the COX reaction, as an alternative substrate with 
similar kinetic parameters (Table 2). From the initial characterization of the enzyme, its catalytic efficiency 
of PGH2 turnover was found to be 310 mM-1 s-1. Like MGST1, mPGES-1 can also catalyze the nucleophilic 
addition of GSH to CDNB, albeit at the relatively low specific activity of 0.8 µmol min-1 mg-1 (116). 
mPGES-1 can also reduce 5-HPETE with a specific activity of 0.043 µmol min-1 mg-1. The latter alternative 
enzymatic activities of mPGES-1 are less efficient than those of other GSTs. Thus, these are most likely 
not relevant biological functions for mPGES-1 in vivo, but they do highlight the evolutionary similarity 
between the enzymes within the MAPEG family (116).  
 
 
Table 2. Steady-state kinetic parameters for human mPGES-1 in the presence of various substrates. Table 
was generated from in J Biol Chem., 278(25), Thorén, S. Human microsomal prostaglandin E synthase-1: 
purification, functional characterization, and projection structure determination. 22199-209, Copyright 
2003 (116). 
 
Substrate kcat (s-1) KM (mM) kcat/ KM (s-1 M-1) 
PGG2 75 ± 4 0.160 ± 0.03 470 x 103 
PGH2 50 ± 6 0.160 ± 0.04 310 x 103 
GSH 21 ± 1 0.71 ± 0.2 30 x 103 
 
 mPGES-1, in conjunction with COX-2, causes a substantial increase in the formation of PGE2 under 
pro-inflammatory conditions. PGE2 is a key mediator of the inflammatory response in the cardiovascular 
system. All clinical hallmarks of inflammation including rubor (redness), tumor (swelling), dolor (pain), 
and fever are promoted by its cellular effects (117). PGE2 is an unstable compound in the circulatory system. 
After only 1.5 min following intravenous injection, less than 5% of PGE2 remains in the circulation due to 
its rapid metabolism to other compounds (118). It is converted in vivo primarily to its inactive metabolite 
13,14-dihydro-15-keto PGE2 by the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) (119). 
Prior to its metabolism, PGE2 is a potent lipid mediator. Its biochemical effects are initiated by binding to 
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one of four GPCRs, or type E prostanoid receptors (EP 1-4). Although an increase of PGE2 is associated 
with pain and fever in an inflammatory state, it also exhibits anti-inflammatory and pro-resolving properties 
under some conditions in vivo. In the late phase of inflammation, PGE2 suppresses the biosynthesis of pro-
inflammatory mediators like TNF-α and IL-1β, while inducing the formation of anti-inflammatory resolvins 
and protectins (120). Furthermore, PGE2 regulates renal blood flow, protects the gastrointestinal tract, and 
promotes wound healing (121). The contrasting biological effects from PGE2 are the result of tissue-specific 
downstream signaling effects from each EP receptor as well as the dual function of individual receptors. 
Specifically, the EP4 receptor mediates pro-inflammatory processes in diseases like arthritis and also 
promotes tumor progression in cancers. Yet, the same receptor is involved in kidney development and 
wound healing, and it contributes to protective processes in the cardiovascular system (122). 
 
mPGES-1 Structure 
 The first crystal structure of mPGES-1 with GSH bound was determined by electron diffraction of 
two-dimensional crystals to 3.5 Å (103). Later, in 2013, a 1.2 Å X-ray crystallographic three-dimensional 
structure was solved, providing greater molecular detail about the enzyme (123) (Figure 13A). Like the 
other MAPEG proteins, mPGES-1 is a homotrimer, consisting of monomers that contain four TMs each. 
Each monomer is stabilized by a group of polar residues, including Lys-26, Asn-74, Asp-75, Arg-110, and 
Thr-114 that are bridged by two water molecules, connecting TMs I, II, and III. An ~15 Å deep cavity 
formed from N-terminal portions of TMs II and IV and the C-terminus of TM I from one monomer and the 
cytoplasmic domain of the adjacent monomer is found at each monomer interface. A GSH molecule is 
bound in a U-shaped conformation in this pocket, forming hydrogen bonds to the side chains of residues 
Arg-73, Asn-74, Glu-77, His-113, Tyr-117, Arg-126, and Ser-127 from TMs II and IV and the Arg-38 side 
chain from TM I (Figure 13B). GSH is an essential cofactor for the stability and catalysis of mPGES-1. 
However, molecular simulations and hybridization experiments determined that only one GSH cofactor can 
bind to one of the pockets and form an active complex at any given time. Therefore, mPGES-1 exhibits 
one-third-of-sites reactivity (124). In each monomer, there is an insert consisting of 20 amino acids between 
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TMs I and II that forms a small positively charged domain (the C-domain), forming part of the active site. 
This is one prominent feature that illustrates the structural diversity observed within the MAPEG family, 
as this extra domain is not observed in other members. The space between the active site and the central 
cavity is blocked by an Arg-73 residue, which is observed to possess two discrete conformations. In one 
conformation, the residue coordinates to a carboxylate group of GSH and results in a separation of the 
cavities. In the alternate conformation, the residue interacts with the carbonyl group of the Leu-69 residue 
of an adjacent molecule and the solvent within the central cavity. 
 
Figure 13. mPGES-1 crystal structure. (A) Each subunit of mPGES-1 containing four transmembrane 
helices is shown in blue, red, or yellow. At the interface of each subunit, the glutathione (GSH) cofactor 
forms noncovalent interactions and stabilizes the enzyme structure. (B) The active site of mPGES-1 with 
GSH. The thiolate (yellow) is in close proximity to Ser-127. Figure generated from PDB 4AL0 (123).  
 
mPGES-1 Mechanism 
 Based on the high resolution, three-dimensional structure of the mPGES-1 enzyme from 2013, a 
mechanism of PGH2 isomerization to PGE2 was proposed. The structural data indicated that the hydroxyl 
group of Ser-127 is responsible for the formation and stabilization of the glutathione thiolate which exerts 
a nucleophilic attack on the oxygen atom at carbon-9 of the PGH2 endoperoxide (123). Initially, it was 
thought that a highly conserved arginine residue was responsible for stabilizing the glutathione thiolate in 
A B
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all members of the MAPEG family. The corresponding arginine residue, Arg-104 is necessary for forming 
the thiolate within the active site of LTC4S, initiating its conjugation to LTA4 (125). Further investigation 
of the mPGES-1 chemical mechanism utilized structural dynamic analysis combined with site-directed 
mutagenesis and activity assays to determine that the isomerization of PGH2 proceeded differently than 
hypothesized, and a new mechanism was proposed (Figure 14). From the structural refinement of the 
mPGES-1 crystal structure, it was determined that a crystallographic water is present in the active site 
(Figure 15).  
 
Figure 14. mPGES-1 catalytic mechanism. Asp-49 forms an interaction with Arg-126, enabling it to 
activate the thiolate of GSH for nucleophilic attack on the oxygen of carbon-9. A water molecule acts as a 
proton shuttle to transfer the GSH proton to the oxygen of carbon-11. Reprinted from Proc Natl Acad Sci 
U.S.A., 113(4), Brock, JS., A dynamic Asp-Arg interaction is essential for catalysis in microsomal 
prostaglandin E2 synthase, 972-977, Copyright 2016, with permission from National Academy of Sciences 
(126). 
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Figure 15. mPGES-1 active site with GSH and crystallographic water. Structural refinement and site-
directed mutagenesis indicated that Ser-127 is not essential for catalysis, but Asp-49 and Arg-126, as well 
as the water molecule are crucial for isomerization. Figure generated from PDB 4AL0 (123,126).  
 
With site-directed mutagenesis, it was also discovered that the Ser-127 proposed to stabilize the GSH 
thiolate was not necessary for enzyme catalysis; however, Asp-49 and Arg-126 are essential for activity. 
Based on this refinement, it was proposed that the Asp-49 modulates Arg-126 to activate the thiolate of 
GSH for its nucleophilic attack on the oxygen of carbon-9. The proton from GSH is then shuttled by the 
crystallographic water to protonate the oxygen of carbon-11. Following its liberation from Arg-126, Asp-
49 can then function as a base to abstract the proton from carbon-9, generating the PGE2 product and 
regenerating GSH (126). Further studies confirmed that Ser-127 is not essential for catalysis, but Asp-49 
and Arg-126 are necessary for substrate isomerization (127). When Arg-126 of mPGES-1 is mutated to 
either alanine or glutamine, the enzyme becomes a reductase, producing PGF2a (128). The mutation to a 
charge-conserved lysine also produces PGF2a, but retains a low level of isomerization activity, indicating a 
positive charge at residue 126 is crucial for catalysis (126).  
 
Arg-38
GSH
H2O
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Ser-127
Arg-126
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 mPGES-1 Inhibition 
 Since the inhibition of the COX enzymes is associated with adverse cardiovascular and 
gastrointestinal side effects, new ways to block the production of pro-inflammatory PGs have been sought. 
The induction of mPGES-1 along with COX-2 and the associated increase in PGE2 production in response 
to inflammatory stimuli has led to considerable interest in mPGES-1 as a therapeutic target for the treatment 
of chronic inflammation (129). Shortly after its identification in the late 1990s, various inhibitors of 
mPGES-1 were developed in both the academic and pharmaceutical sectors (Figure 16). However, the 
development of potent mPGES-1 inhibitors for the treatment of chronic inflammatory diseases has been a 
challenge. Although some compounds have been developed which potently inhibit human mPGES-1, they 
substantially lose potency for the rat orthologue. Previous studies determined that this interspecies 
difference is due to the residues Thr-131, Leu-135, and Ala-138 in human mPGES-1, which function as 
gate keepers for the active site of the enzyme. These residues are located on TM IV and line the entrance 
to the active site between two subunits in the protein trimer. The corresponding residues in the rat isoform 
are bulkier and thus restrict access of the inhibitors into the active site (130). The human mPGES-1 crystal 
structure revealed that Arg-52 and His-53 in the C-domain may also contribute to the differences in inhibitor 
potency between human and rat isoforms but this was not confirmed by point mutations (123). 
 The first reported inhibitor of mPGES-1 was in 2001, MK-886, and two inhibitors have recently 
entered clinical trials. However, no mPGES-1 inhibitors have reached the market for treating chronic 
inflammation (131). An oxicam inhibitor developed by Pfizer Inc., PF-9184, was quite potent for mPGES-
1 inhibition, exhibiting an IC50 value of 16.5 nM in the presence of the recombinant human enzyme and 
having no effect on either COX-1 or COX-2 (132). Another inhibitor developed by Angelini Research 
Center was the carbazole benzamide, AF3442. The compound inhibited mPGES-1 in a specific manner 
with an IC50 value of 60 nM for the recombinant human enzyme and 410 nM in LPS-stimulated monocytes. 
The inhibitor did not appear to affect the redirection of PGH2 into other prostanoid synthase pathways (133). 
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Figure 16. Chemical structures of mPGES-1 inhibitors. 
 
Another potent phenanthrine imidazole inhibitor, MF63, developed by Merck Frosst displayed an IC50 of 
1.3 nM for the human enzyme with a high selectivity over other prostanoid synthases. Moreover, 
gastrointestinal toxic side effects typically observed with NSAIDs were not caused by the administration 
of MF63 (134). Some of the most recent mPGES-1 inhibitors have exhibited sufficient potency in inhibiting 
both the human and rat enzymes in cell-free assays, in vitro cellular assays, and also in vivo models of 
inflammation. The pyrazolone known as compound II from NovaSAID AB inhibited PGE2 production in 
synovial fibroblasts from patients having rheumatoid arthritis (135). Another inhibitor, a benzoimidazole 
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known as compound III from NovaSAID AB, exhibits a submicromolar IC50 in the presence of both human 
and rat recombinant enzymes. mPGES-1 inhibition was also investigated in mouse macrophages and A549 
cells. In these systems, levels of other prostanoids were decreased, with most PGH2 being shunted to the 
prostacyclin pathway. In contrast, mPGES-1 knock-out mice displayed an increased production of TXA2 
(136). More recently, additional analogues of the first mPGES-1 inhibitors have been optimized, and more 
inhibitors have been developed. From using X-ray crystallography and a high-throughput screening method 
with differential static light scattering (DSLS), four distinct inhibitors were further investigated to elucidate 
their structure-activity relationships with the enzyme and ultimately improve the efficacy of future 
inhibitors. From the crystal structures, it was observed that the inhibitors share a common binding mode, 
where each forms interactions with TM IV of one monomer and their head groups insert into the active site 
pocket above GSH (137). 
 Hydrogen-deuterium exchange mass spectrometry (HDX-MS) has been utilized to map the binding 
sites of different types of inhibitors to mPGES-1 (138). One inhibitor, glutathione sulfonate (GSO3-), was 
shown to bind in the GSH binding site with an IC50 of 1.8 mM. With the introduction of the three additional 
oxygen atoms of the sulfonate group, the GSH binding site is disrupted, as indicated by the HDX-MS 
results. Other inhibitors that were examined included MF63, MK-886 from Merck (139), and an inhibitor 
known as compound I from NovaSAID AB (130). Based on dynamic HDX-MS studies, the majority of the 
enzyme peptides that are involved in inhibitor binding are found within a hydrophobic cleft consisting of 
TM I from one subunit and TMs II and IV from a neighboring subunit. It was shown that the three critical 
residues on TM IV that differ between the human and rat enzymes exhibited enhanced HDX kinetics in the 
presence of the aforementioned inhibitors (excluding GSO3-, which competes for the GSH binding site), 
indicating that this particular region is crucial for inhibitor binding (138). 
 In addition to synthetic inhibitors of mPGES-1, the degradation product of prostaglandin D2, 15-
deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), has been shown by HDX-MS kinetics to inhibit mPGES-1 by 
covalent modification of Cys-59 and by noncovalent interaction at the PGH2 substrate binding site (140). 
The initial spontaneous dehydration of PGD2 gives rise to the intermediate compound PGJ2, which will 
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then isomerize to form Δ12-PGJ2. This product spontaneously loses an additional molecule of water to yield 
15d-PGJ2 (141). Using a Cys-59-Ala mutant mPGES-1 enzyme, it was observed that inhibition with the 
15d-PGJ2 substrate was reversible with increasing concentrations of PGH2 with an IC50 value of 12 µM. 
Based on these studies, 15d-PGJ2 most likely inhibits mPGES-1 through its covalent adduction to the Cys-
59 residue of the enzyme. However, since the concentration of 15d-PGJ2 in the cell is unknown, no 
conclusion can be made regarding whether the covalent modification of MPEGS1 in vivo is of any 
significance (140). 
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PURPOSES OF THESE STUDIES 
 
COX-2 and mPGES-1 are both upregulated in the presence of pro-inflammatory stimuli and growth 
factors. Consistent with its role in inflammation, COX-2 is a therapeutic target through inhibition by 
NSAIDs and coxibs. In recent years, mPGES-1 has become another therapeutic target to selectively inhibit 
production of the pro-inflammatory PGE2. However, only recently two mPGES-1 inhibitors entered clinical 
trials, and none has yet reached the market. 
The studies described herein further investigate the molecular mechanisms of both COX-2 and 
mPGES-1. Although NSAIDs have been thoroughly studied, it is still unknown how the occupancy of an 
inhibitor in one subunit can affect substrate oxygenation in the opposite subunit. The phenomenon of 
substrate-selectivity has been exhibited by various NSAIDs and many crystal structures of these inhibitors 
with COX-2 have been solved. However, this structural data is insufficient for defining the mechanistic 
properties of substrate-selectivity. 
In Chapter III of this dissertation, two COX-2 inhibitors, ibuprofen and mefenamic acid, were used 
to assess the substrate-selective inhibition of COX-2 with AA and 2-AG substrates. The inhibitors bind to 
the enzyme active site in different orientations with regard to the position of their carboxylates. The NSAID 
flurbiprofen is structurally similar to ibuprofen and binds to the enzyme in the same orientation yet is not 
substrate-selective. Likewise, meclofenamic acid is similar in structure to mefenamic acid yet is also not 
substrate-selective. Therefore, the substrate-selectivity of ibuprofen and mefenamic acid for AA and 2-AG 
oxygenation were investigated with various experimental parameters, including a preincubation period of 
each inhibitor with the enzyme. Furthermore, the hydroperoxide PPHP was added to some reaction mixtures 
to examine the effect of enzyme activation in the presence of each inhibitor. 
In Chapter IV, a COX-2•FAAH dual inhibitor, ARN2508, was utilized for structural and kinetic 
studies. Previously, it was shown that ARN2508 inhibits FAAH as well as both COX isoforms. These 
studies utilized a racemic mixture of the inhibitor. Herein, the (S)-enantiomer of ARN2508 was crystallized 
in complex with COX-2 in order to observe how the inhibitor bind to the enzyme active site. The inhibitory 
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kinetics of each ARN2508 enantiomer were also investigated. Various experimental conditions were tested 
including the absence or presence of a preincubation of the inhibitor with the enzyme. Mutations of active 
site residues were also completed to investigate how they affected binding of ARN2508 to the enzyme and 
its subsequent inhibitory kinetics.  
In Chapter V, efforts to investigate the structural properties of the COX-2 homodimer were began 
in collaboration with the Karolinska Institutet. A membrane mimetic, nanodiscs, was used for the 
reconstitution of recombinant COX-2 and subsequent analysis by negative stain EM and Cryo-EM. The 
nanodisc platform provided a suitable environment for keeping the COX-2 enzyme stable in solution as 
well as exhibiting a sufficient molecular size for EM analysis. The structural analysis of COX-2 in 
nanodiscs could reveal more about its heterodimeric function. Although many X-ray crystal structures of 
the enzyme in complex with substrates and inhibitors have been solved, there is still limited information 
regarding the cross-talk of residues at the dimer interface of the enzyme. With recent improvements in 
Cryo-EM, it could be possible to investigate the structural dynamics of COX-2 in the presence of various 
substrates and/or inhibitors. 
In Chapter VI, the molecular mechanisms of mPGES-1 were investigated. The development of 
potent mPGES-1 inhibitors for the treatment of chronic inflammatory diseases has been a challenge. Only 
recently, a high-resolution crystal structure of the enzyme was solved and proposed to involve the activation 
of a glutathione (GSH) thiolate by a Ser-127 residue in the active site. Here, site-directed mutagenesis 
studies conducted in collaboration with the Karolinska Institutet revealed that alternate residues in the 
enzyme active site, Asp-49 and Arg-126, are crucial for activity. Moreover, Ser-127 is not necessary for 
substrate isomerization. Based on these studies and further molecular refinement of the crystal structure, 
the molecular dynamics of the enzyme are better understood, setting the stage for the design of more potent 
mPGES-1 inhibitors.  
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CHAPTER II 
 
 
MATERIALS AND METHODS 
 
 
Materials 
 
 Buffer salts and common chemical reagents were purchased in the highest available quality from 
commercial vendors. Detergents were from Affymetrix Anatrace, Santa Clara, CA. AA was purchased from 
Nu-Chek Prep, Inc., Elysian, MN. Heme was purchased from Frontier Scientific, Inc., Logan, UT. 2-AG, 
PGE2-d4, 11b-PGE2, PGH2, PPHP, malondialdehyde, (S)-flurbiprofen, and a-linolenic acid were purchased 
from Cayman Chemical, Ann Arbor, MI. PGE2-G-d5 was synthesized from chemicals purchased from 
Sigma-Aldrich, St. Louis, MO as previously described (54). Phosphatidylcholine was purchased from 
Avanti Polar Lipids, Alabaster, AL. Linearized baculovirus DNA and related reagents were purchased from 
Expressions Systems, LLC., Davis, CA. Sf9 cell culture reagents were from Life Technologies, Carlsbad, 
CA. 
 
Methods 
 
Recombinant murine COX-2 expression and purification 
 The cDNA of recombinant murine COX-2 (mCOX-2) was cloned into a pVL-1393 transfer vector 
and co-transfected with linearized baculovirus DNA (Autographa californica nuclear polyhedrosis virus). 
The virus containing the mCOX-2 gene was amplified in Spodoptera frugiperda Sf9 cells and the amplified 
virus stocks were subsequently used to infect larger Sf9 cell cultures. Cell cultures at a density of 1.2 x 106 
cells/mL were infected with amplified virus and grown in an incubator shaker at 27°C, 140 rpm for 72 h. 
Cells were harvested by centrifugation and resuspended in homogenization buffer (25 mM Tris, pH 8.0, 
250 mM sucrose, 1 mM EDTA, 1 mM diethyldithiocarbamate (DEDTC)). Cells were stirred until 
homogenous, and a 15% n-Decyl-b-D-maltoside (C10M) aqueous solution was added to the mixture 
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dropwise, giving a final C10M concentration of 1.5%. Cells were stirred for one additional hour at 4°C. 
Cells were sonicated (60% amplitude, 50% duty cycle, 2 minutes on, 4 minutes off) for 3-4 cycles using a 
Qsonica Q500 sonicator. Cellular debris was cleared by centrifugation in a Beckman-Coluter JA-20 rotor 
at 16,000 rpm, 4 °C, 30 min. Cellular lysate was loaded onto a Q Sepharose Anion Exchange column (28 
mL column volume) equilibrated with Buffer A (20 mM Tris, pH 8.0, 0.1 mM EDTA, 0.1 mM DEDTC, 
0.15% C10M). Following the lysate load, the column was washed with Buffer A at a flow rate of 2 mL/min 
until the absorbance (A280) returned to baseline. To elute mCOX-2, a linear gradient of Buffer A and an 
increasing concentration of Buffer B (20 mM Tris, pH 8.0, 1 M NaCl, 0.1 mM EDTA, 0.1 mM DEDTC, 
0.15% C10M), 40% B over 12 column volumes, was applied, and peak fractions (6 mL) were collected. 
Fractions containing mCOX-2 were concentrated to approximately 2 mL and further purified with gel 
filtration on a HiLoad 16/600 Superdex 200 pg column (120 mL column volume) in size-exclusion buffer 
(25 mM Tris, pH 8.0, 0.1 mM EDTA, 50 mM NaCl, 0.3% n-Octyl-b-D-glucoside (b-OG)), at a flow rate 
of 0.5 mL/min. Fractions (5 mL) containing the eluted protein were collected, pooled, and concentrated to 
approximately 1 mL, and frozen in aliquots at -80°C.  
 The above procedure was for the purification of mCOX-2 without an affinity tag. To optimize the 
purification, a C-terminal hexahistidine-tag (His6-tag) was cloned in frame with the mCOX-2 gene 
sequence. To purify the tagged enzyme, cell transfection and harvest were performed as described above. 
Harvested cells containing his-tagged mCOX-2 were resuspended in homogenization buffer (25 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 10 mM imdizaole, 250 mM sucrose, 10% glycerol, 1.5% C10M 
(added dropwise)) and stirred until homogeneous. Cells were lysed as described above.  Cell lysate 
was added to a gravity column containing Ni-NTA affinity resin, equilibrated with equilibration buffer (25 
mM Tris, pH 8.0, 150 mM NaCl, 10 mM imidazole). Nonspecific proteins were washed with 10 column 
volumes of wash buffer (25 mM Tris, pH 8.0, 150 mM NaCl, 50 mM imidazole, 5% glycerol, 0.3% b-OG). 
mCOX-2 was eluted from the Ni-NTA column with five column volumes of elution buffer (wash buffer 
containing 150 mM imidazole). Eluted enzyme was concentrated to approximately 1 mL and purified with 
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gel filtration in size-exclusion buffer. Fractions were collected, concentrated to approximately 1 mL, and 
frozen in aliquots at -80°C. 
 
mCOX-2 Peroxidase Activity Assay 
 To assess the POX activity of purified mCOX-2, a colorimetric assay observing the oxidation of 
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) in the presence of hydrogen peroxide was 
used. The assay was performed at room temperature (22 °C) on a Beckman-Coulter DU800 
spectrophotometer. Each sample (total reaction volume of 1 mL) contained: 100 mm Tris, pH, 8, 15 nM 
mCOX-2, 30 nM heme, and 1 mM ABTS. The absorbance at 417 nm was measured as a blank. Next, H2O2 
was added to a final concentration of 50 µM, the solution was quickly mixed, and the absorbance at 417 
nm was monitored for two minutes. The slope of the linear portion of the absorbance spectrum was used to 
calculate the POX activity of purified mCOX-2. 
 
mCOX-2 Heme Oxidation Assay 
 The oxidation state of heme reconstituted with mCOX-2 was investigated spectroscopically based 
on a previously published method (91). In a quartz cuvette, 1 µM wild-type mCOX-2 was mixed with 1 
µM heme in 100 mM Tris, pH 8.0. The formation of the oxidized heme radical cation was initiated by the 
addition of H2O2 to a final concentration of 15 µM. The total reaction volume of each sample was brought 
to 600 µL with buffer. Wavelength scans from 390 to 620 nm were recorded. To monitor the ability to act 
as reducing co-substrates, various concentrations of inhibitors were pre-incubated with 1 µM wild-type 
mCOX-2 and 1 µM heme for at least 3 mins at room temperature in 100 mM Tris, pH 8.0. The absorbance 
at 409 nm was recorded for each sample as a blank before adding H2O2 to initiate heme oxidation.  
Wavelength scans were recorded every 20 s to monitor the change in absorbance at 409 nm, corresponding 
to the reduction of compound II back to the resting ferric state. 
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mCOX-2 Activity and Inhibition Assay by Mass Spectrometry 
 For assessing the catalytic activity of mCOX-2, 195 µL of 15 nM enzyme was reconstituted with 
30 nM heme in buffer containing 100 mM Tris, pH 8 and 500 µM phenol. Samples were kept on ice until 
ready for use. Each sample was equilibrated at 37°C for at least three minutes before the addition of 
substrate. The desired substrate (5 µL, AA or 2-AG) in dimethyl sulfoxide (DMSO) was added to the 
reaction buffer. If the hydroperoxide activator 5-phenyl-4E-pentenyl-1-hydroperoxide (PPHP) was used in 
the assay, the enzyme volume buffer was reduced to 190 µL and 10 µL of a mixture containing substrate 
and PPHP was added to the buffer. The final concentration of PPHP in each sample was 1 µM. After adding 
substrate, the reaction mixture was quickly vortexed, and the reaction proceeded for 10 secs (or other 
specified reaction time). Each reaction was quenched with the addition of 200 µL of ice-cold ethyl acetate 
containing 0.5% glacial acetic acid and 300 nM internal standards, either PGE2-d4 or PGE2-G-d5. Each tube 
was thoroughly mixed and frozen at -80°C for at least 30 mins. The top organic layer was collected and 
evaporated to dryness under N2 gas. The samples were then reconstituted in 150 µL of 50% methanol/water 
and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Each sample was 
injected onto a Phenomenex Luna C18 (2) column (50 x 2 mm, 5 µM) with a gradient elution of 30-100% 
solvent B over 3 mins at a flow rate of 400 µL/min. Solvent A contained 5 mM ammonium acetate, pH 3.6 
and Solvent B contained 94% acetonitrile and 6% Solvent A. Selected reaction monitoring for the following 
transitions were analyzed: m/z 370 ® 317 (PGE2/D2), m/z 374 ® 321 (PGE2-d4), m/z 444 ® 391 (PGE2/D2-
G), and m/z 449 ® 396 (PGE2-G-d5). For the COX-2 inhibition assays, the same analysis of PGs and PGGs 
was utilized. Inhibitors (mefenamic acid, ibuprofen, flurbiprofen, ARN2508) were dissolved in DMSO, and 
5 µL of each was added to the reaction buffer and preincubated with COX-2 for a designated time. 
Alternatively, inhibitors were added simultaneously with substrate in a total volume of 10 µL DMSO to 
each reaction sample. 
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Inhibition of COX-2 Gly-533 mutants by (S)-ARN2508 
Inhibition kinetics with Gly-533 mutants were analyzed using UV-Visible Spectroscopy on a 
Beckman-Coulter DU800 Spectrophotometer. Enzyme (200 nM monomer) was resuspended in 590 µL of 
assay buffer (100 mM Tris, pH 8.0) with one equivalent of heme. LNA (50 µM) was then added, mixed 
and the absorbance at 235 nm was recorded for 2 min after approximately 5 s of dead time. Inhibitors in a 
DMSO stock were added for various preincubation times prior to adding substrate.   
 
Reconstitution and Purification of mCOX-2 in Nanodiscs 
 The incorporation of purified mCOX-2 into nanodisc membrane mimetics was investigated in 
collaboration with the laboratory of Dr. Hans Hebert at the Karolinska Institutet in Huddinge, Sweden. To 
prepare the nanodiscs, a molar ratio of 1300:10:1 of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC):membrane-scaffold protein (MSP1E3D1):mCOX-2 (dimer) was used. POPC lipids (10 mg) in 
chloroform were dried under a stream of N2 and then overnight in a vacuum desiccator. The following day, 
263 µL of 500 mM sodium cholate in nanodisc buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 0.5 mM EDTA) 
was added to the dried lipids. Lipids were vortexed and sonicated until homogeneously resuspended into 
the buffer. Non-tagged MSP1E3D1 protein was added to the mixture along with purified mCOX-2 and b-
OG detergent. The final concentrations of each component in the mixture were: 16 mM POPC, 32 mM 
cholate, 123 µM MSP1E3D1, 12 µM mCOX-2 (dimer), and 0.53% b-OG in a total volume of 822 µL. The 
components were mixed at 4 °C for at least one hour. The mixture was split into two separate Eppendorf 
tubes and to each tube, 330 mg of SM-2 Bio-Beads (BioRad) was added. Following mixing overnight at 4 
°C, Bio-Beads were removed by centrifugation. The supernatant containing mCOX-2-constituted nanodiscs 
was exchanged with nanodisc buffer without the addition of EDTA (20 mM Tris, pH 7.5, 150 mM NaCl) 
using centrifugal protein concentrator conical tubes. Following buffer exchange, the mixture was purified 
by immobilized metal affinity chromatography (IMAC) by incubating with Ni-NTA resin at 4 °C for at 
least one hour. The mixture was added to a gravity column, and the beads were washed with buffer 
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containing 20 mM Tris, pH 7.5, 150 mM NaCl, and 50 mM imidazole. mCOX-2 nanodiscs were eluted 
from the resin with buffer containing 20 mM Tris, pH 7.5, 150 mM NaCl, and 200 mM imidazole. Eluted 
nanodiscs were concentrated to 500 µL and purified with size-exclusion chromatography in nanodisc 
buffer. The purity of fractions from the size-exclusion purification was assessed with SDS-PAGE. 
Moreover, the incorporation of mCOX-2 into nanodiscs was assessed using native PAGE in a 4-16% Bis-
Tris gel (Novex). Samples were mixed with 4 X native PAGE sample buffer (Invitrogen). Blue native 
PAGE was performed by using light cathode buffer (native PAGE running buffer (Invitrogen) with 0.001% 
Coomassie G-250) in the cathode tank and native PAGE running buffer in the anode tank. Gels were run at 
a constant voltage of 150 V. 
 
COX-2:POPC Nanodisc Cryo-Electron Microscopy 
Vitrified samples were prepared using an FEI Vitrobot at 22 °C and 92% humidity. 3 µL of COX-
2:POPC nanodisc solution (final concentration ~35 µg/mL) was applied onto 400 mesh glow-discharged 
Quantifoil R2/4 grids (Quantifoil Micro Tools GmbH, Germany). The sample was incubated on the grid 
for 10 s, blotted for 2-3 s and plunge-frozen into liquid ethane. Frozen grids were stored in liquid nitrogen. 
For cryo-electron microscopy, the grids were loaded into a Gatan 626 cryo-holder and transferred to a JEOL 
JEM2100F transmission electron microscope operated at 200 kV. Images were recorded at 2, 5-4 µm 
defocus on a DE-20 direct electron detector (Direct Electron, LP, USA) at a magnification of × 50,000, 
resulting in a sampling distance of 1.24 Å/pixel. Each image was exposed for 2 s using a frame rate of 20 
frames/s. The total accumulated dose/image was approximately 40-50 e-/Å2. 
 
COX-2:POPC Nanodisc Cryo-Electron Microscopy Image Processing 
 The effect of sample drift for each frame was compensated using the DE_process_frames-2.7.1.py 
script. Image processing was performed using EMAN2 software. The templates for auto-picking were 
selected manually from the images and the auto-picked images were checked manually to remove bad 
particles. The total dataset consisted of 244 images and 65,164 particles. 2D class averages were calculated 
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from a smaller set of particles to see the quality of data. The atomic structure of AA bound to the COX-2 
active site (PDB: 3HS5) low-pass filtered to 60 Å was used as an initial model for 3D refinement. The 3D 
refinement was performed without any symmetry and with C2-symmetry. An initial round of 3D refinement 
was performed using a downscaled (2.48 Å/pixel) dataset, aiming at low resolution. The final map of the 
first 3D refinement was used as a starting model for further 3D refinements, using the full-sized (1.24 
Å/pixel) dataset as input, aiming at higher resolution. 
 
mPGES-1 expression and purification in E. Coli 
 Initial kinetic studies with mPGES-1 were based on recombinant human enzyme expressed in E. 
coli. The human mPGES-1 gene with a C-terminal His6-tag was subcloned into a pET-21b expression 
vector. Silent mutations of the codons for Arg-40, Arg-74, and Arg-123 corrected for codon bias. The 
plasmid was transformed into Rosetta 2 (DE3) E. coli competent cells and transfected cells were cultured 
in a minimal medium (20 mM Na2HPO4, 20 mM KH2PO4, 90 mM NaCl, 200 mM NH4Cl, 130 µM CaCl2, 
1 mM MgSO4, 0.4% glucose, 0.3% casamino acids). Cells were grown in an incubator shaker at 37 °C, 250 
rpm. When an OD600 of 0.7 was achieved, cell cultures were cooled to 18 °C, and protein expression was 
induced by the addition of 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). The cells were cultured 
further at 18 ºC, 200 rpm for approximately 36 additional hours. Cells were harvested by centrifugation at 
6,500 x g, 4 °C, 6 mins, and stored at -20 °C. Frozen cell pellets were resuspended in cold lysis buffer (50 
mM KH2PO4, pH 8.0, 300 mM KCl, 1 mM GSH, 1 mM DTT, 1 mM EDTA, 10% glycerol). Lysozyme was 
added to a final concentration of 0.2 mg/mL, and cells were stirred for 2 h at 4 ºC. Cells were sonicated on 
ice using a Qsonica Q500 sonicator (60% amplitude, 50% duty cycle, 2 mins on, 4 mins off) until the 
mixture was homogeneous. The cellular debris was cleared by centrifugation at 10,000 x g, 4°C, 30 mins. 
The membrane fractions from the cell lysate were isolated using ultracentrifugation at 100,000 x g, 4°C, 2 
h. The supernatant was discarded, and membrane pellets were washed with cold 50 mM KH2PO4, pH 8.0. 
The membranes were solubilized in cold extraction buffer (50 mM KH2PO4, pH 8.0, 300 mM KCl, 1 mM 
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GSH, 5 mM imidazole, 10% glycerol, 0.5% n-Dodecyl-β-D-maltoside (b-DDM)). The enzyme was 
solubilized by gentle stirring overnight at 4 ºC. The solubilized enzyme was incubated with equilibrated 
Ni-NTA agarose and gently stirred at 4 °C for at least one hour. The resin was added to a gravity column 
for purification. Extraction buffer containing 35 mM imidazole was added to wash the non-specific proteins 
from the column, and the His6-tag mPGES-1 was eluted by adding extraction buffer containing 250 mM 
imidazole. The fractions were collected, and the presence of the protein was verified by SDS-PAGE. The 
eluted protein was concentrated using an Amicon pressure concentrator (MWCO = 10 kDa) to 
approximately 10 mL and dialyzed against 1 L of ion-exchange buffer (50 mM KH2PO4, pH 7.0, 1 mM 
GSH, 20% glycerol, 1% polyoxyethylene(10)dodecyl ether) at 4 °C, overnight. The dialyzed protein was 
then applied to sulfopropyl sepharose equilibrated with ion-exchange buffer in a gravity column. The 
protein was washed with a similar buffer containing 0.1% DDM, or 1% 3-[(3-
Cholamidopropyl)dimethylammonio]-1-Propanesulfonate (CHAPS), and then eluted with a similar buffer 
containing 100 mM KCl and 0.05% DDM, or 0.5% CHAPS. The eluted protein was concentrated using an 
Amicon pressure concentrator (MWCO = 10 kDa) until the A280 was approximately 1.2, giving a final 
concentration of approximately 1 mg/mL. The enzyme was then dialyzed overnight at 4 °C in a buffer 
containing 50 mM KH2PO4, pH 7.0, 300 mM KCl, 1 mM GSH, 1 mM DTT, 7.5% glycerol, 1% CHAPS. 
Protein was aliquoted and stored at -20 °C for future use. In alternate enzyme preparations and purifications, 
the final purification step with ion-exchange and final dialysis replaced 1 mM GSH with 1 mM of various 
GSH analogues, GSO3-, γ-L-Glu-L-SerGly (GOH), or γ-L-Glu-L-AlaGly (GH). The purification of each 
enzyme preparation was verified by SDS-PAGE and Western blotting using a QIAexpress Anti-His 
antibody for the detection of His6 tagged proteins. Since mPGES-1 is unstable when the cofactor-binding 
site is unoccupied, apo-mPGES-1 experiments were not possible. Therefore, all experiments described 
herein are with mPGES-1 complexed with either GSH or one of its analogues. 
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mPGES-1 expression and purification optimization in Sf9 cells 
 To enhance the expression of recombinant human mPGES-1, a baculovirus expression system for 
the infection of Sf9 cells similar to that described above for murine COX-2 was utilized. Briefly, the cDNA 
of recombinant human mPGES-1 containing a C-terminal His6-tag was cloned into a pVL-1392 transfer 
vector and co-transfected with linearized baculovirus DNA (Autographa californica nuclear polyhedrosis 
virus). The virus containing the mPGES-1 gene was amplified in Spodoptera frugiperda Sf9 cells and the 
amplified virus stocks were subsequently used to infect larger Sf9 cell cultures. Cell cultures at a density 
of 1.2 x 106 cells/mL were infected with amplified virus and grown in an incubator shaker at 27°C, 140 rpm 
for 72 h. Cells were harvested by centrifugation and purified using the aforementioned purification 
procedure of human mPGES-1 expressed in E. coli. Slight modifications were implemented to increase the 
yield of pure, homogeneously folded enzyme. Following the second purification step with ion-exchange 
chromatography, fractions were pooled, concentrated to approximately 2 mL, and purified with gel 
filtration on a HiLoad 16/600 Superdex 200 pg column in size-exclusion buffer containing 50 mM KH2PO4, 
pH 7.0, 300 mM KCl, 1 mM GSH, 1 mM DTT, 7.5% glycerol, 0.05% b-DDM. Fractions (5 mL) were 
collected, pooled, and concentrated in small aliquots and frozen at -20 °C for future use. 
 
mPGES-1 Site-Directed Mutagenesis 
 For preparing the Asp-49-Ala, Arg-126-Ala, Ser-127-Ala, and Ser-127-Cys mutants, the wild-type 
human mPGES-1 gene in the pVL-1392 transfer vector was used as a template for standard site-directed 
mutagenesis with PCR. The following primers were used for each mutant:  
Mutant Primer 
Asp-49-Ala (Forward) GCCAACCCCGAGGCTGCCCTGAGACAC 
Asp-49-Ala (Reverse) GTGTCTCAGGGCAGCCTCGGGGTTGGC 
Arg-126-Ala (Forward) GCGTGCACCCATCGCCTCCGTGACCTAC 
Arg-126-Ala (Reverse) GTAGGTCACGGAGGCGATGGGTGCACGC 
Ser-127-Ala (Forward) TGCACCCATCCGCGCCGTGACCTACAC 
Ser-127-Ala (Reverse) GTGTAGGTCACGGCGCGGATGGGTGCA 
Ser-127-Cys (Forward) TGCACCCATCCGCTGCGTGACCTACAC 
Ser-127-Cys (Reverse) GTGTAGGTCACGCAGCGGATGGGTGCA 
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Mutated plasmids were transfected into XL1 Blue supercompetent cells and plasmid sequences were 
verified with sequencing (GenHunter, Nashville, TN). 
 
Synthesis of γ-L-Glu-L-SerGly (GOH) and γ-L-Glu-L-AlaGly (GH) 
 Both analogues of GSH, GOH and GH, were synthesized according to a published method (142). 
Briefly, the protected active g-ester of L-glutamic acid was prepared by the reaction of N-t-BOC-L-glutamic 
acid a-benzyl ester and 4-nitrophenol, followed by glacial acetic acid. The dicyclohexylurea was removed 
by vacuum filtration, and solvent was evaporated from the filtrate to leave an oily residue. The oil was 
dissolved in hot ethanol, and the product crystallized upon cooling overnight. The needles formed from 
precipitation were the protected active g-ester, which was then coupled to either L-serylglycine or L-
alanylglycine in 33% pyridine/H2O. Following stirring overnight, NaHCO3 in H2O was added, and the 
reaction mixture was extracted with ethyl acetate. The organic layer was back-extracted with additional 
H2O. The aqueous fractions were pooled together, lowered to pH 2.5 with 3 M HCl, and stored at 4 °C. The 
granulated oily product contained the protected peptide, which was then deprotected by dissolving in 
anhydrous trifluoroacetic acid. Anhydrous HBr gas was bubbled through the solution for 30 mins on ice, 
then at room temperature for 2 h. Excess solvent was removed by flash evaporation and the remaining tan 
oil was washed with diethyl ether and dried in a vacuum desiccator. The product was purified by anion-
exchange with BioRad AG1-X2 acetate beads. The product was added to the beads in a gravity column and 
the beads were then washed with 50 mM acetic acid. The product was eluted from the beads by flowing 
through a linear gradient of 50 mM to 1 M acetic acid. Fractions containing the purified product were pooled 
and lyophilized three times with H2O to yield a white hygroscopic powder. Final purified product was 
characterized using both 1H-NMR and 13C-NMR at the Vanderbilt Small Molecule NMR Facility. 1H-NMR 
and 13C-NMR spectra revealed that the chemical shifts corresponded to literature values.  
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Glutathione Transferase Activity Assays 
 A glutathione transferase assay of recombinant human mPGES-1 activity was based on a previously 
published method (116). Briefly, a reaction mixture containing 100 mM KH2PO4, pH 6.5, 4 mM GSH, 1 
µM purified mPGES-1, and 0.1% b-DDM was mixed and brought to a volume of 990 µL. The absorbance 
at 340 nm was recorded as a blank measurement. The conjugation of GSH to the substrate CDNB was 
initiated by the addition of 10 µL of 200 mM CDNB in ethanol. The reaction mixture was quickly mixed, 
and the absorbance at 340 nm was monitored at 22 °C for 20 mins. The background reaction contained the 
same mixture without the addition of enzyme and was subtracted from the activity in the presence of 
enzyme. 
 
Prostaglandin E Synthase Activity Assay by Mass Spectrometry 
 The isomerization of PGH2 to PGE2 was detected with LC-MS/MS, with the method being 
modified from a previously published procedure (143). PGH2 in acetone was distributed in small aliquots 
and kept on dry ice until use in each reaction. To initiate isomerization, 100 µL of a 100 nM purified 
mPGES-1 enzyme stock solution in reaction buffer (100 mM KH2PO4, pH 7.5, 1 mM GSH, 1% glycerol 
and 0.05% b-DDM) was added to each PGH2 aliquot. Each sample was reacted for one min on ice, and 
unreacted PGH2 was decomposed to 12-HHT and malondialdehyde (MDA) by the addition of 400 µL of 
quench buffer (25 mM FeCl2, 50 mM citric acid, pH 3.0, and 0.5 µM 11b-PGE2 as an internal standard). 
Each sample was purified using disposable C18 solid-phase extraction columns and eluted in 100% 
methanol. Methanol was evaporated under N2 gas, and samples were resuspended in 20% acetonitrile/H2O 
and analyzed by LC-MS/MS with a Phenomenex Luna 3.0 µ, C18(2), 100 Å column (150 x 2.00 mm) 
equipped with a Phenomenex Security Guard Cartridge Kit, eluting at a flow rate of 350 µL/min using 
mobile phase A (H2O + 0.1% formic acid) and mobile phase B (CH3CN + 0.1% formic acid). A gradient 
of 31.2 to 42.5% B was run over 14.3 minutes. Using negative electrospray ionization, the detection of 
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PGE2, 11b-PGE2, and PGD2 was confirmed by the SRM of the transition m/z 351.2 ® 271.2 on a 
ThermoFinnigan TSQ triple-quadrupole mass spectrometer. 
 
Prostaglandin E Synthase Activity Assay by Fluorescence 
 An alternative method for assessing mPGES-1 activity examined the degradation of the PGH2 
substrate as opposed to observing the formation of the PGE2 product. Similar to the LC-MS/MS-based 
method, PGH2 substrate was distributed in small aliquots in tubes on dry ice. To initiate the reaction, 100 
µL of a 100 nM purified mPGES-1 enzyme stock solution in reaction buffer (100 mM KH2PO4, pH 7.5, 1 
mM GSH, 1% glycerol, and 0.05% b-DDM) were added to each PGH2 aliquot. Each sample was reacted 
for one min on ice, and unreacted PGH2 was decomposed to 12-HHT and MDA by the addition of 100 µL 
of quench buffer (100 mM FeCl2, 500 mM citric acid, pH 2.0). To each sample, 100 µL of a solution 
containing 15 mM thiobarbituric acid (TBA) in 80 mM KH2PO4, pH 2.0 was added and heated to 80 °C for 
30 mins. Precipitate from each sample was removed by centrifugation. A 200 µL aliquot of each reaction 
mixture was transferred to a 96-well plate, and fluorescence of the resulting MDA-TBA complex was 
recorded in a BioTek Synergy MX plate reader. Samples were excited at 485 nm, and emissions were 
observed at a wavelength of 545 nm. 
 
Stopped-flow Kinetics of mPGES-1 Thiolate Formation 
 Stopped-flow kinetic experiments were performed in collaboration with the laboratory of Dr. Ralf 
Morgenstern at the Karolinska Institutet in Stockholm, Sweden. Initially, a solution of 50 µM of purified 
mPGES-1 was rapidly injected in an Applied Photophysics SX20 stopped-flow cell against a solution of 
the same buffer containing 20 mM GSO3-. With a 1:1 mixing ratio, the final concentrations of the enzyme 
and competitor were 25 µM and 10 mM, respectively. The change in absorbance at 239 nm was observed 
for various time points ranging from 5 seconds to 300 seconds to observe any potential drift that might 
occur. Recombinant enzyme 
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potential competition of the thiolate with the oxygen analogue in the active site of the enzyme. Further 
stopped-flow experiments were performed following the concentration of enzyme to a final concentration 
of 150 µM. The enzyme was rapidly mixed against GSO3- or GOH, each at a final concentration of 10 mM. 
 
Peptide Sequencing of mPGES-1 by Tandem Mass Spectrometry 
 The peptides of purified mPGES-1 were sequenced using a previously published method with 
modifications (138). Purified mPGES-1 was dialyzed into a buffer containing 50 mM KH2PO4, pH 7.0), 
200 mM KCl, 1 mM GSH (or GOH, GH), 7.5% glycerol, and 0.5% CHAPS. The enzyme solution was 
initially brought to a concentration of approximately 0.2 mg/mL (12 µM) in H2O at 0 °C. Enzymatic 
digestion of the enzyme was performed on ice for seven minutes by adding 580 µM pepsin in H2O. The 
digested peptides were separated by reversed-phase HPLC on a Phenomenex Aeris Peptide 3.6 µ XB-C18 
column (50 x 2.1 mm) submerged in an ice bath and eluted at a flow rate of 300 µL/min with a 30 min 
gradient of 5-50% CH3CN and 0.4% formic acid. The peptides were analyzed on a LTQ tandem mass 
spectrometer using positive electrospray ionization, with scans of m/z 300 to 1500. Peptides were sequenced 
with data-dependent tandem MS/MS by collision-induced dissociation (CID). The identity of each peptide 
was verified using the computational program PEAKS Client 7 (Bioinformatics Solutions Inc.), which 
determines the identity of peptide fragments based on raw data acquisition. PEAKS then predicts peptide 
fragmentation based on the protease used for digestion, the FASTA sequence for the protein, and the MS 
instrument and parameters used. Experimental fragmentation patterns were matched with predicted peptide 
fragmentation. Selected peptides were further verified using MassXpert MS analysis software which 
compares experimental peptide parent masses with all possible peptides within the protein. Experimental 
fragmentation spectra were then compared to theoretical fragmentation patterns of all possible peptides by 
the ProteinProspector program MS-Product. Verified peptides were then compiled to generate a peptide 
coverage map. 
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CHAPTER III 
 
MOLECULAR BASIS OF CYCLOOXYGENASE-2 INHIBITION BY MEFENAMIC ACID AND 
IBUPROFEN 
 
 
 
 NSAIDS inhibit the COX enzymes by binding in the COX active site of the catalytic subunit, the 
allosteric subunit, or both and preventing the oxygenation of substrates. Numerous NSAIDS have been 
developed, including nonspecific inhibitors of both COX-1 and COX-2, as well as coxibs that selectively 
inhibit COX-2. Some NSAIDs inhibit COX by binding rapidly and reversibly to the enzyme. Others bind 
rapidly to the enzyme in an initial step followed by one or more slower steps to form a tight enzyme-
inhibitor complex. Furthermore, some inhibitors of the COX enzymes are substrate-selective, in that they 
are rapidly reversible, weak inhibitors of AA oxygenation, but potent, time-dependent inhibitors of 
endocannabinoid oxygenation. Presumably, the substrate-selective inhibitors bind in the allosteric subunit 
of the enzyme and induce a conformational change in the catalytic subunit that prevents the oxygenation of 
endocannabinoids but not AA. Inhibition of AA oxygenation requires lower affinity binding of the inhibitor 
in the catalytic subunit (88).  
 Ibuprofen and mefenamic acid were both reported to be rapid, reversible inhibitors of AA 
oxygenation, but potent, tight-binding inhibitors of endocannabinoid oxygenation. Although their 
inhibitory mechanisms were initially thought to be similar, the potency and mode of binding of each 
inhibitor appear to differ from those of the another  (88). In the crystal structure of mCOX-2 with a racemic 
mixture of ibuprofen, only the (S)-enantiomer of the inhibitor was bound, consistent with its having higher 
affinity for the enzyme. The carboxylate of (S)-ibuprofen forms interactions with the constriction site 
residues, Arg-120 and Tyr-355, and mutation of these residues affects inhibitor binding (144). The inhibitor 
mefenamic acid has been shown to bind in the COX active site in an inverted orientation, similar to that of 
diclofenac and lumiracoxib, in that its carboxylate forms interactions with Tyr-385 and Ser-530. 
Flurbiprofen and meclofenamic acid are structurally similar inhibitors to ibuprofen and mefenamic acid, 
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respectively. However, flurbiprofen and meclofenamic acid are both slow, tight-binding inhibitors and are 
not substrate-selective (89,91). The differences in the substrate-selectivity of these structurally similar 
inhibitors have not yet been explained. The studies herein seek to further understand the molecular 
mechanisms of substrate-selective inhibition by inhibitors such as mefenamic acid and ibuprofen. 
 
Results 
Substrate-Selective Inhibition of Cyclooxygenase-2 by Mefenamic Acid and Ibuprofen 
 In order to assess the substrate-selective inhibition of ibuprofen and mefenamic acid, activity assays 
were conducted, and product formation was quantified by LC-MS/MS. For all assays presented here, 15 
nM mCOX-2 was reconstituted with 2 equivalents of heme in each reaction mixture. Reactions were 
initiated with the addition of 5 µM of either AA or 2-AG and allowed to proceed for 10 s before being 
quenched with organic solvent containing deuterated internal standards. The short reaction time was chosen 
in order to minimize the total amount of substrate turnover and limit enzyme self-inactivation.  
 Other experimental parameters were varied to investigate the substrate selectivity of inhibition. 
Since inhibition of 2-AG oxygenation has been reported to be time-dependent whereas inhibition of AA 
oxygenation is not, assays were conducted both with and without a 15 min preincubation of inhibitor and 
enzyme. Another experimental variable that was evaluated was the absence or presence of the 
hydroperoxide activator PPHP. The presence of inhibitors can theoretically increase the enzyme lag phase 
by slowing the reaction or directly interfering with enzyme activation. Since a short reaction time of 10 s 
was used, a significant lag phase would produce misleading kinetic data. This effect would be expected to 
be greater for 2-AG than AA inhibition, as higher peroxide concentrations are required to activate the 
enzyme when 2-AG is the substrate (90). A concentration of 1 µM PPHP was reported to be sufficient to 
maximize substrate oxygenation of either AA or 2-AG by COX-2 in in vitro kinetic assays (64). When 
included, PPHP was added simultaneously with each substrate. 
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As indicated in Figures 17 and 18 and Table 3, both inhibitors were more potent for inhibiting 2-
AG oxygenation than AA oxygenation under all conditions tested except one (ibuprofen yielded the same 
IC50 for inhibition of 2-AG and AA oxygenation in the presence of PPHP following preincubation of 
inhibitor with the enzyme). This result was consistent with a previous report in which the substrate 
selectivity of the inhibitors was evaluated in the absence of added hydroperoxide using an oxygraph 
instrument (88). In the case of ibuprofen, preincubation of the inhibitor with the enzyme increased potency 
for 2-AG oxygenation by ~7-fold regardless of the presence or absence of PPHP, and addition of PPHP 
reduced inhibitor potency by ~1.5-fold with or without preincubation (based on IC50 values). In contrast, 
preincubation increased inhibitor potency for AA oxygenation to a much greater extent (>200-fold and 
>1,400-fold in the absence or presence of PPHP, respectively). For AA oxygenation, inclusion of PPHP 
had no significant effect on the potency of ibuprofen in the absence of preincubation, but it increased 
inhibitor potency ~5-fold when preincubation was included in the assay (Figure 17, Table 3).  
 
Figure 17. IC50 curves for mCOX-2 inhibition by ibuprofen (IB). In each experiment, 15 nM mCOX-2 was 
reconstituted with 30 nM heme and used for oxygenation of 5 µM substrate. Substrate oxygenation was 
tested in the absence (blue) or presence (red) of 1 µM of the hydroperoxide activator PPHP. Inhibition of 
AA oxygenation was observed with no pre-incubation of ibuprofen with COX-2 (A) or a 15 min pre- 
incubation of ibuprofen with COX-2 (C). Inhibition of 2-AG oxygenation was observed with no pre-
incubation of ibuprofen with COX-2 (B) or a 15 min pre-incubation of ibuprofen with COX-2 (D). 
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Table 3. IC50 values (µM) (95% confident range) for AA and 2-AG oxygenation in the presence of 
ibuprofen and mefenamic acid. For each substrate with or without pre-incubation, IC50 values (µM) are 
listed in the absence (blue) or presence (red) of 1 µM PPHP. 
 
Ibuprofen    
 No pre-incubation  No pre-incubation 
5 µM AA 260 (220-300) 5 µM 2-AG 0.86 (0.69-1.1) 
5 µM AA 330 (280-400) 5 µM 2-AG 1.3 (1.0-1.8) 
 15 min pre-incubation  15 min pre-incubation 
5 µM AA 1.1 (0.61-2.3) 5 µM 2-AG 0.12 (0.12-0.13) 
5 µM AA 0.23 (0.07-0.53) 5 µM 2-AG 0.20 (0.17-0.23) 
    
Mefenamic acid    
 No pre-incubation  No pre-incubation 
5 µM AA 100 (89-120) 5 µM 2-AG 0.05 (0.04-0.06) 
5 µM AA 110 (100-120) 5 µM 2-AG 0.53 (0.41-0.71) 
 15 min pre-incubation  15 min pre-incubation 
5 µM AA 0.12 (0.08-0.18) 5 µM 2-AG 0.01 (0.01-0.01) 
5 µM AA 88 (43-180) 5 µM 2-AG 0.07 (0.04-0.10) 
 
For mefenamic acid using 2-AG as the substrate, preincubation of the enzyme with inhibitor 
resulted in an increase in potency similar to what was seen with ibuprofen (~5-fold and ~8-fold in the 
absence and presence of PPHP, respectively). In the absence of PPHP, preincubation caused a much greater 
(>800-fold) increase in potency for AA oxygenation than 2-AG oxygenation as was seen for ibuprofen, but 
in the presence of PPHP, preincubation did not alter mefenamic acid potency when AA was the substrate.  
When 2-AG was the substrate, PPHP had a greater effect on mefenamic acid potency (~7 to 10-fold increase 
in IC50) than was observed for ibuprofen. In the case of AA oxygenation, PPHP had no effect on mefenamic 
acid potency in the absence of a preincubation, as was observed for ibuprofen. However, PPHP produced 
a >700-fold decrease in mefenamic acid potency for AA oxygenation when the enzyme was preincubated 
with the inhibitor (Figure 18, Table 3). 
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Figure 18. IC50 curves for mCOX-2 inhibition by mefenamic acid (MEF). In each experiment, 15 nM 
mCOX-2 was reconstituted with 30 nM heme and used for oxygenation of 5 µM substrate. Substrate 
oxygenation was tested in the absence (blue) or presence (red) of 1 µM of the hydroperoxide activator 
PPHP. Inhibition of AA oxygenation was observed with no pre-incubation of mefenamic acid with COX-
2 (A) or a 15 min pre-incubation of mefenamic acid with COX-2 (C). Inhibition of 2-AG oxygenation was 
observed with no pre-incubation of mefenamic acid with COX-2 (B) or a 15 min pre-incubation of 
ibuprofen with COX-2 (D). 
 
 In summary, the results for 2-AG inhibition were consistent for the two inhibitors with some 
quantitative differences. Both inhibitors were more effective following preincubation with the enzyme, and 
both were less effective in the presence of PPHP, with the reduction in potency being substantially greater 
for mefenamic acid than for ibuprofen. These findings are consistent with past reports that inhibition of 2-
AG oxygenation by these inhibitors is time-dependent (88). They also suggest that the mechanism of 
inhibition by both inhibitors is dependent to some degree on suppression of peroxide-dependent enzyme 
activation, and this appears to be more important for mefenamic acid than for ibuprofen. In the case of AA, 
both inhibitors are more potent following preincubation with the enzyme, a result that contradicts prior 
reports that both are rapidly reversible inhibitors of AA oxygenation (88). The effects of PPHP were also 
harder to explain in the case of AA oxygenation than 2-AG oxygenation. PPHP increased the potency of 
ibuprofen following preincubation of the inhibitor with the enzyme, an unexpected finding, as eliminating 
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an artificially extended lag phase by adding peroxide would be expected to reduce, rather than increase, 
apparent inhibitor potency. In contrast, PPHP had the opposite effect on the potency of inhibition by 
mefenamic acid, suggesting a significant difference between the two inhibitors with regard to their effects 
on enzyme activation when AA is the substrate. 
Since the experiments investigating inhibitor potency in the absence or presence of PPHP suggested 
that mefenamic acid strongly affects enzyme activation when the enzyme is preincubated with the inhibitor, 
an additional experiment was performed to evaluate substrate oxygenation differences in the absence or 
presence of mefenamic acid (100 nM), with or without PPHP, at various reaction times following a 15 min 
preincubation (Figure 19). For the DMSO control samples, PPHP appeared to slightly suppress enzyme 
activity, likely due to the promotion of enzyme suicide inactivation from an increased peroxide 
concentration. However, there does not appear to be a lag phase in product formation in the absence of 
inhibitor or PPHP, indicating that there is likely an adequate level of peroxide contamination in both 
substrates to rapidly activate the enzyme. In contrast, in the absence of PPHP, mefenamic acid appears to 
cause a lag in AA oxygenation since less product is made in the first 10 s than is made in the 5 s period 
between 10 and 15, or in the 10 s period between 20 and 30. In fact, less product is made in the absence of 
PPHP in the first 10 s than in the presence of PPHP even though PPHP seems to suppress the reaction by 
itself. Therefore, at this concentration, mefenamic acid extends the lag phase for AA oxygenation, and the 
effect is so severe for 2-AG that no product is formed at all. However, increasing the lag phase is not the 
only mechanism for inhibition, as less product is formed from both substrates when PPHP is added to each 
reaction and the lag phase is eliminated.  
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Figure 19. Time course assay for COX-2 substrate oxygenation in the presence of 100 nM mefenamic acid 
(MA) (red) or DMSO (blue). 15 nM mCOX-2 was reconstituted with 30 nM heme and pre-incubated at 37 
°C for 15 mins in the absence or presence of inhibitor. (A) AA oxygenation in the absence of PPHP. (B) 2-
AG oxygenation in the absence of PPHP. (C) AA oxygenation in the presence of PPHP. (D) 2-AG 
oxygenation in the presence of PPHP. 
 
 
Mefenamic Acid Acts as a Reducing Co-substrate of COX-2 Heme  
 
 Based on the previous experiments, it appeared that mefenamic acid affects the lag phase of the 
enzymatic reaction, and that it does so by a mechanism in addition to simply slowing the rate of the reaction, 
as indicated by the fact that PPHP has a much greater effect on the potency of mefenamic acid than 
ibuprofen. One possibility is that mefenamic acid acts as a reducing co-substrate of the oxidized heme 
prosthetic group. Mefenamic acid’s susceptibility to oxidation has been illustrated by its cytochrome P450-
mediated conversion to quinoneimines (145). In fact, Malkowski and co-workers determined that 
mefenamic acid and other fenamate inhibitors can act as reducing co-substrates that reset the heme of 
activated COX-2 to its resting ferric state, and they can destabilize the catalytic tyrosyl radical that connects 
the enzyme’s peroxidase activity to its cyclooxygenase activity. Their experiments determined that the 
fenamates bind in an inverted orientation in the COX active site, forming interactions with Tyr-385, and 
they hypothesized that these interactions could facilitate tyrosyl radical destabilization. Due to the greater 
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hydroperoxide tone required to activate COX-2 for 2-AG oxygenation than AA oxygenation, they further 
proposed that mefenamic acid-mediated substrate-selective inhibition could be explained by its ability to 
suppress peroxide-dependent enzyme activation (91). To further explore this hypothesis and to test its 
applicability to other classes of inhibitors, additional experiments were performed to observe the oxidation 
state of the heme in the presence of mefenamic acid or ibuprofen. 
In order to investigate whether mefenamic acid or ibuprofen could function as a co-substrate to 
reduce the heme back to its resting state, the soret peak absorance of the heme moiety was monitored with 
UV-Visible spectroscopy. When heme is oxidized by the peroxide, there is a shift in absorbance from 409 
to 415 nm. If the heme is returned to its reduced ferric state, a stronger absorbance at 409 nm will be 
observed. To initially test the effect of inhibitors on the heme oxidation state, various concentrations of 
either ibuprofen or mefenamic acid were pre-incubated with 1 µM mCOX-2 and 2 µM heme. The oxidation 
of the heme was initiated by adding 15 µM H2O2, and the absorbance at 409 nm was recorded. Every 20 s 
thereafter, the absorbance at 409 nm was recorded again. The incubation of ibuprofen with COX-2 elicited 
no increase in absorbace at 409 nm, indicating that it was unable to reduce the heme back to its ferric state. 
Similarly, incubating either 100 nM or 1 µM mefenamic acid with the enzyme had no effect on absorbance 
at 409 nm. However, increasing the concentration of inhibitor to 10 µM or higher resulted in net heme 
reduction (Figure 20). This result is not surprising, as an excess of peroxide concentration in comparison to 
mefenamic acid concentration can reoxidize the heme. 
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Figure 20. Heme oxidation in the presence of either ibuprofen (IB) or mefenamic acid (MA) and 1 µM 
COX-2 and 2 µM heme. Soret peak absorbance at 409 nm was recorded as a function of time following 
addition of 15 µM H2O2. 
 
 
A similar experiment continuously monitored absorbance at 409 nm following heme oxidation with an 
increased concentration of H2O2 (50 µM) and concentrations of each inhibitor up to 500 µM. Ibuprofen still 
showed no ability to reduce the heme back to its resting state, whereas higher concentrations of mefenamic 
acid (100 and 500 µM) increased the soret peak absorbance at 409 nm. 
 
Figure 21. Heme oxidation in the presence of either ibuprofen (IB) or mefenamic acid (MA) and 1 µM 
COX-2 and 2 µM heme. Soret peak absorbance at 409 nm was recorded as a function of time following 
addition of 50 µM H2O2. 
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Discussion 
 
 Even though the concept of substrate-selective inhibition of COX-2 by various NSAIDs has been 
well studied, there are underlying mechanistic properties that are still unclear. As noted above, the original 
model proposed to explain substrate-selective inhibition of COX-2 is that high affinity, time-dependent 
binding of inhibitor to the allosteric site blocks 2-AG oxygenation whereas lower affinity, rapidly reversible 
binding of inhibitor to the catalytic site is required to block AA oxygenation (88). That model was called 
into question, at least in the case of fenamic acid inhibitors, when Orlando et al. proposed that substrate-
selective inhibition could be explained on the basis of the fenamates’ ability to act as reducing co-substrates 
for the enzyme (144). The requirement for higher peroxide tone to sustain 2-AG oxygenation would make 
it more susceptible than AA oxygenation to this mechanism of inhibition (90). This model predicts that 
addition of exogenous hydroperoxide should reduce inhibitor potency, and that the effect should be greater 
for 2-AG oxygenation than for AA oxygenation, thus reducing or eliminating the differential potency of 
inhibition for 2-AG versus AA. The experiments performed here were designed to further explore these 
distinct, but not mutually exclusive models. 
 
Mefenamic Acid Acts as a Reducing Co-substrate of COX-2 Heme  
 The model proposed by Orlando et al. depends on the ability of the fenamates to act as reducing 
co-substrates for the enzyme. To determine if this mechanism applies to other substrate-selective inhibitors, 
the abilities of mefenamic acid and ibuprofen to serve as co-reductants of COX-2 were compared. The POX 
and COX reactions are chemically linked together through the heme prosthetic group, which is oxidized by 
peroxides and reduced by the abstraction of an electron from Tyr-385 to initiate the COX reaction. A 
subsequent one electron reduction by the reducing co-substrate returns the heme back to its resting ferric 
state. To investigate the oxidation state of the heme moiety in the POX active site in the presence of each 
inhibitor, UV-Visible spectroscopy was utilized to observe the soret peak of the heme prosthetic group. The 
pre-incubation of the enzyme with ibuprofen did not affect the soret peak absorbance shift after the addition 
of peroxide. However, the addition of mefenamic acid elicited an increase in the soret peak absorbance at 
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409 nm, indicating that the inhibitor was acting as a co-substrate to reduce the heme back to its ferric state. 
As could be predicted, only concentrations of mefenamic acid in excess of peroxide concentration were 
able to achieve net reduction of the heme. Therefore, mefenamic acid functions as a reducing co-substrate 
of the heme, which likely plays a role in its mechanism of inhibition, in agreement with previous 
experiments (91). The mechanism by which mefenamic acid disrupts the activation state of COX-2 certainly 
depends on its susceptibility to oxidation. In addition, mefenamic acid binds to COX-2 in an inverted 
orientation with its carboxylate forming interactions with Ser-530 and the catalytic Tyr-385. It is possible 
that this proximity to Tyr-385 enables mefenamic acid to directly interfere with tyrosyl radical formation 
or to promote radical quenching. Ibuprofen shares neither of these traits, and consistently, does not act as a 
COX-2 co-reductant. Thus, these experiments confirm the original reports of Orlando et al. that mefenamic 
acid can reduce the heme of COX-2, but they also demonstrate that this mechanism does not apply to all 
substrate-selective inhibitors. It is also important to note that COX-2 activity is typically measured in the 
presence of excess phenol, which serves as reducing co-substrate for the enzyme. Consequently, it is not 
clear to what degree mefenamic acid or any other inhibitor usurps this function under standard assay 
conditions. 
 
Substrate-Selective Inhibition of Cyclooxygenase-2 by Mefenamic Acid and Ibuprofen 
 The experiments that gave rise to the data in Table 3 were designed to more thoroughly evaluate 
the original model of substrate-selective inhibition in the context of a potential role for peroxide tone. The 
data support some, but not all of the original model. In the absence of preincubation, there is a marked 
difference in potency for inhibition of AA versus 2-AG oxygenation for both ibuprofen and mefenamic 
acid whether or not PPHP is present. This suggests that, consistent with the model, each inhibitor is 
interacting with the enzyme at different sites to block oxygenation of AA versus 2-AG. However, the data 
also reveal a significant time-dependency for AA oxygenation that is not in agreement with prior reports. 
An understanding of this discrepancy, obviously of concern, may lie in the different methods used to assay 
enzyme activity. In the current study, COX-2 activity was measured on the basis of product formation at a 
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fixed time point using a relatively short reaction time of 10 s. The addition of PPHP was used to eliminate 
the lag phase of the reaction, so that full enzyme activity would be achieved throughout that 10 s period. 
Previous experiments that were used to develop the original model of substrate-selective inhibition 
quantified AA oxygenation from O2 uptake using an oxygen electrode, a method that monitors reaction 
progress on a continuous basis. As no hydroperoxide was included in the reaction mixtures in these studies, 
reaction rate was quantified on the basis of the most rapidly descending portion of the O2 concentration 
curve following the lag phase. This method, which has been widely used to assay COX activity, suffers 
from the fact that no effort is made to control for variation in enzyme activation or inactivation rates. Thus, 
there is no way to know whether or not the measured rate is a true reflection of the initial rate of the 
enzymatic reaction, and one cannot be assured that steady state is ever approximated. The assay used here 
attempted to eliminate some of these variables, but it is not currently known if this difference in 
methodology can explain the discrepant results. Regardless of the source of the differences, however, the 
current data suggest that for both AA and 2-AG inhibition and for both ibuprofen and mefenamic acid, the 
enzyme forms a more tightly bound complex upon preincubation with the enzyme. Ironically, this effect 
(increase in potency) was greater for inhibition of AA than for 2-AG, so that preincubation reduced, to 
some extent, the differential observed between the IC50 values for inhibition of the two substrates for both 
inhibitors. In other words, substrate-selectivity was reduced by preincubating enzyme with inhibitor for 
both ibuprofen and mefenamic acid. 
 PPHP had a significant effect on the potencies of both inhibitors when the enzyme had been 
preincubated with the inhibitors before adding substrate. Presumably, this corresponds to the most potent 
enzyme-inhibitor complex that can be formed. In the case of 2-AG, inhibitor potency was always lower in 
the presence of PPHP, and the effect was greater for mefenamic acid than for ibuprofen. These results are 
consistent with the ability of inhibitors to impede peroxide-dependent enzyme activation as proposed by 
Orlando, et al (144). In the case of ibuprofen, the effect of the inhibitor is likely due to its ability to slow 
activation simply by slowing the reaction, whereas mefenamic acid can also directly interfere with 
activation by serving as a reducing co-substrate. In contrast, the effects of PPHP on inhibition of AA 
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oxygenation are not straight-forward. PPHP increased the potency of ibuprofen when AA was the substrate, 
so inclusion of PPHP essentially eliminated the differential in IC50 between AA and 2-AG oxygenation for 
ibuprofen, thus apparently eliminating substrate-selective inhibition. This would appear to support the 
hypothesis of Orlando, et al, that substrate-selective inhibition is dependent on peroxide tone. However, the 
PPHP-mediated increase in potency of ibuprofen for AA oxygenation is totally inconsistent with this model. 
In the case of mefenamic acid, PPHP decreased the potency of inhibition of AA oxygenation, as would be 
expected, but that decrease (>700-fold) was greater than the decrease observed for 2-AG oxygenation (~7-
fold). Thus, PPHP actually increased the differential in IC50 values between AA and 2-AG oxygenation 
rather than decreasing it, as the model proposed by Orlando, et al would predict. 
 
Conclusions 
 Kinetic evaluation of the COX reaction is complicated by the requirement for product-dependent 
activation, suicide inactivation, and the presence of two functionally distinct binding sites that can 
accommodate both inhibitors and substrates.  From the experiments described here, preincubation time-
dependence and peroxide tone affected the differences in potency for AA versus 2-AG, and this was true 
for both ibuprofen and mefenamic acid. The results both partially support and call into question prior 
models of substrate-selective inhibition. Notably, inhibition of AA oxygenation by both ibuprofen and 
mefenamic acid was found to be time-dependent to a greater degree than inhibition of 2-AG oxygenation. 
Furthermore, although a role for peroxide tone in substrate-selective inhibition was confirmed, the effects 
of PPHP on the potencies of each inhibitor were not totally consistent with expectations, and the importance 
of this mechanism varies between inhibitors. Thus, these experiments have raised as many questions as 
they have answered, and further work will be required to fully explain the mechanism(s) of substrate-
selective inhibition.  
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CHAPTER IV 
 
 
DUAL CYCLOOXYGENASE-FATTY ACID AMIDE HYDROLASE INHIBITOR EXPLOITS 
NOVEL BINDING INTERACTIONS IN THE CYCLOOXYGENASE ACTIVE SITE 
 
 
 Numerous inhibitors have been developed for the COX enzymes to inhibit oxygenation of their 
substrates. The inhibition of COX-1 prevents the formation of PGs, which are primarily pro-inflammatory 
mediators. Moreover, the inhibition of COX-2 prevents formation of PGs, and prevents the oxygenation of 
2-AG, which is an endogenous agonist for the CB1 and CB2 receptors. More recently, dual inhibitors of the 
COX-2 enzyme and other enzymes that metabolize bioactive lipids to pro-inflammatory mediators have 
been developed. These inhibitors target COX-2 and 5-LOX, COX-2 and sEH, and COX-2 and fatty acid 
amide hydrolase (FAAH) (146-148). The use of NSAIDs like flurbiprofen can often cause undesirable side 
effects, particularly gastrointestinal toxicity. By inhibiting both COX-2 and FAAH, it is possible to 
circumvent this toxicity by preventing the producting of PGs, while preventing the hydrolysis of AEA to 
AA and ethanolamide. AEA, like 2-AG, is an endogenous agonist of the cannabinoid receptors and exhibits 
analgesic effects in vivo. The data presented herein described the inhibition of COX-2 by ARN2508, a dual 
COX-2•FAAH inhibitor. Based on structural and kinetic data, it was determined that ARN2508 adopts a 
unique binding pose in the COX-2 active site which has not been observed for other NSAIDs. Ser-530 and 
Gly-533 in the active site are also key determinants in its inhibitory kinetics. 
 
Results 
Structural analysis of COX-2 with (S)-ARN2508 
 To investigate the structural characteristics of ARN2508 in complex with mCOX-2, a crystal 
structure with the (S)-enantiomer was solved at a resolution of 2.27 Å by molecular replacement using the 
high-resolution monomer model of mCOX-2 in complex with naproxen (PDB: 3NT1). The potency of the 
(R)-enantiomer for mCOX-2 inhibition is low, similarly to (R)-flurbiprofen. Hence, a crystal structure for 
(R)-ARN2508 was not solved. ARN2508 is a compound consisting of a common biphenyl core, a part of 
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the NSAID flurbiprofen for COX inhibition and a part of the FAAH inhibitor, URB597 (Figure 22). The 
propionic acid group needed for COX inhibition is attached to one side of the biphenyl core, whereas a 
carbamate substituent necessary for FAAH inhibition is attached to the opposite side of the central core. 
Various hydrophobic substituents were also attached to the distal carbamate nitrogen and tested for their 
ability to inhibit COX-2.  
 
FIGURE 22. Chemical structures of (R)- and (S)-flurbiprofen and (S)-ARN2508. The alkyl carbamate 
substituent of ARN2508 is needed for FAAH inhibition (red box). The propionic acid moiety is needed for 
COX inhibiton (blue box). ARN2508 also contains a common biphenyl core for inhibition of both enzymes 
(black box). 
 
 From the crystal structure of (S)-ARN2508 in complex with mCOX-2, it was observed that the 
flurbiprofen moiety of ARN2508 sits in the hydrophobic channel of the enzyme’s active site with the same 
binding mode that is adopted by flurbiprofen in COX-1 and COX-2 (51,89,149). Thus, the carboxylate 
moiety of ARN2508 lies at the constriction of the active site, ion-pairing to Arg-120 and hydrogen-bonding 
to Tyr-355, and the aromatic rings project upwards toward Tyr-385. However, hydrogen bond formation 
with ARN2508’s carbamate group requires an upward displacement of the side chain of Ser-530 in the 
COX-2•(S)-ARN2508 complex relative to its position in the COX-2•flurbiprofen complex. Additional 
hydrogen bonds form between Tyr-385 and the oxygen atoms of ARN2508’s carbamate group. The alkyl 
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chain of ARN2508 reaches deeply into the distal portion of the cyclooxygenase channel between helices 2 
and 17, making hydrophobic interactions with various residues including Phe-205, Phe-209, Phe-210, Val-
228, Ile-341, Val-344, Ile-377, Phe-381, and Leu-534 (Figure 23). 
 
Figure 23. Crystal structure of (S)-ARN2508 in the COX-2 channel. The OMIT Fo-Fc map is contoured at 
3 s; the inhibitor is colored in yellow sticks and the interacting residues of COX-2 are illustrated in light 
cyan. Potential H-bonds are presented with dashed lines. 
 
Potency, isoform-selectivity, and substrate-selectivity of ARN2508 enantiomers 
It was previously reported that racemic ARN2508 has an IC50 value of approximately 12 nM for 
COX-1 and 430 nM for COX-2 (147). To further assess the potency of the inhibitor, each enantiomer was 
individually tested for both ovine COX-1 (oCOX-1) and COX-2 inhibition. The results (Figure 24) 
indicated that the potency of the (S)-enantiomer of ARN2508 (IC50 = 7.0 nM) for COX-1 inhibition is much 
greater than that of the (R)-enantiomer (IC50 = 4.6 µM). Similarly, using 5 µM AA as substrate, the (S)-
enantiomer was the more potent of the two against COX-2, achieving complete inhibition of AA 
oxygenation with an IC50 of approximately 39 nM (Figure 25A), whereas the (R)-enantiomer inhibited the 
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enzyme by ~50% at 10 µM and failed to reach complete inhibition at the highest concentration tested (100 
µM). Thus, as previously reported for the racemic mixture, each enantiomer of ARN2508 exhibits a small 
degree of COX-1 selectivity. The potency of the (S)-enantiomer for 2-AG oxygenation by COX-2 (IC50 = 
21 nM) was greater than that for AA oxygenation, but only by approximately two-fold (Figure 25B). In 
contrast, (R)-ARN2508 exhibited an ~30-fold higher inhibitor potency for 2-AG (IC50 = 0.34 µM) versus 
AA oxygenation and completely blocked 2-AG oxygenation. These results indicate that the (R)-enantiomer 
is a substrate-selective COX-2 inhibitor. 
 
Figure 24. Inhibition of oCOX-1 with ARN2508. Oxygenation of 5 µM AA by oCOX-1 was assessed by 
quantification of enzymatic product formation utilizing LC-MS/MS. Enzyme was preincubated with each 
enantiomer of ARN2508 for 10 min. AA (5 µM) was allowed to react for 10 s before quenching with 
organic solvent containing deuterated internal standards. Results are the mean ± S.D. of triplicate 
determinations.  
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FIGURE 25. Inhibition of mCOX-2 with ARN2508, with or without pre-incubation.  Oxygenation of 5 
µM AA (A) or 5 µM 2-AG (B) by mCOX-2 was assessed by quantification of enzymatic product formation 
utilizing LC-MS/MS. Each enantiomer of ARN2508 was pre-incubated for 10 min (10 m) or added 
simultaneously (0 m) with substrate. Each substrate was allowed to react for 10 s before quenching with 
organic solvent containing deuterated internal standards. Results are the mean ± S.D. of triplicate 
determinations. 
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Time-dependency of AA and 2-AG oxygenation inhibition by ARN2508 enantiomers 
As most highly potent COX inhibitors are time-dependent, initial experiments included an 
arbitrarily chosen 10 min preincubation period prior to substrate addition. To further explore the time-
dependency of ARN2508, various concentrations of each enantiomer were added simultaneously with 
either AA or 2-AG to COX-2, reactions were quenched after 10 s, and products were analyzed using LC-
MS/MS. The data indicate that COX-2 inhibition by the (R)-enantiomer is essentially time-independent for 
both AA and 2-AG oxygenation, as preincubation had minimal effect on the observed IC50 values or extent 
of inhibition observed. In contrast, COX-2 inhibition by the (S)-enantiomer is strongly time-dependent, as 
indicated by IC50 values in the nM range for both AA and 2-AG oxygenation following preincubation, but 
failure to reach even 50% inhibition in the absence of preincubation at the concentrations tested. (Figure 
25). 
 To further assess the kinetic mechanism of ARN2508-mediated COX-2 inhibition, various 
concentrations of the (S)-enantiomer were preincubated with wild-type COX-2 for different time periods, 
and the activity of the enzyme was measured. A plot of enzyme activity versus time for each inhibitor 
concentration exhibited pseudo-first order kinetics (Figure 26A), and the observed first order rate constants 
for each curve (kobs) were plotted against inhibitor concentration. The resulting data (Figure 26B) failed to 
yield the hyperbolic curve that is expected from the two-step model. A possible explanation is that the two-
step model is correct, but insufficient concentrations of inhibitor were used to fully delineate the hyperbola. 
Indeed, fitting of the data to this model yields a first step dissociation constant of 220 µM and inhibition 
rate constant of 41 min-1, corresponding to an overall kinetic efficiency (kon/KI) of 0.18 min-1·µM-1. These 
values are, at best, only estimates, as evaluation of much higher inhibitor concentrations is necessary to 
fully define the curve. Unfortunately, solubility limitations prevented this evaluation. An alternative 
explanation is that the plot is linear rather than hyperbolic, suggesting that ARN2508 does not follow the 
typical two-step kinetic mechanism. In this case, the binding process would more likely occur in a single 
step, or if multistep, the first step is rate-limiting. The slope of the line (0.11 min-1·µM-1) provides an 
estimate of the second order rate constant for the binding of inhibitor to enzyme in this model. Regardless 
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of which model is correct, the formation of the inhibitory (S)-ARN2508•COX-2 complex occurs 
substantially more slowly than formation of the inhibitory complex of (S)-flurbiprofen with COX-2, which 
exhibits a reported overall kinetic efficiency of 6 min-1·µM-1 (150). 
 
FIGURE 26. Kinetics of the time-dependent inhibition of mCOX-2 by (S)-ARN2508. (A) Various 
concentrations of (S)-ARN2508 were incubated with wild-type mCOX-2 for the indicated preincubation 
times before the addition of 5 µM AA. Each enzymatic reaction proceeded for 10 s before being quenched 
with organic solvent containing deuterated internal standards. Oxygenation of AA was assessed by 
quantification of enzymatic product formation utilizing LC-MS/MS. (B) Observed first order rate constants 
were plotted against inhibitor concentration to obtain the kinetic parameters for the enzyme-substrate 
interaction. Both linear and hyperbolic fits are shown. Results are the mean ± S.D. of triplicate 
determinations.  
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Importance of Tyr-355 in determining the potency of ARN2508 
 The Tyr-355 residue of COX-2 is within hydrogen-bonding distance of the carboxylate group of 
ARN2508. To evaluate the importance of this interaction, ARN2508 was tested for its ability to inhibit AA 
oxygenation by Y355F. As seen in Figure 27, the Y355F mutation had only modest effects on the kinetics 
of the enzyme with AA as substrate. The potency of (S)-ARN2508 decreased slightly for the Y355F mutant, 
as indicated by an approximately 2.5-fold increase in IC50. The potency of the (R)-enantiomer decreased 
more substantially; failure to achieve more than 50% inhibition at the highest inhibitor concentration tested 
(50 µM) precluded determination of an IC50 value. These findings differ significantly from those obtained 
with other previously reported carboxylate-containing NSAIDs, including indomethacin, meclofenamic 
acid, and ibuprofen which exhibit substantially reduced potency against the COX-2 Y355F enzyme, and 
they support the hypothesis that hydrogen bond formation with Tyr-355 contributes only modestly to the 
binding affinity of (S)-ARN2508. 
 
FIGURE 27. Inhibition of mCOX-2 mutants with ARN2508. Oxygenation of 5 µM AA by wild-type, 
Y355F, S530A, or S530T mCOX-2 enzymes was assessed by quantification of enzymatic product 
formation utilizing LC-MS/MS. Each enzyme was preincubated with the indicated enantiomer of ARN2508 
for 10 min. AA was allowed to react for 10 s before quenching with organic solvent containing deuterated 
internal standards. Results are the mean ± S.D. of triplicate determinations. 
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Role of Ser-530 in ARN2508 binding to COX-2 
 The presence of a reactive carbamoyl group and the known ability of ARN2508 to covalently 
modify FAAH suggested the possibility that the inhibitor also covalently modifies COX-2. The proximity 
of the carbamoyl group of ARN2508 to Ser-530 observed in the crystal structure led to the hypothesis that 
a covalent modification might occur at that residue in solution. However, LC-MS/MS analysis of the tryptic 
peptides of COX-2 that had been incubated with the inhibitor failed to reveal the mass shift expected from 
the addition of ARN2508 to Ser-530. Despite obtaining ample sequence coverage (84%) that includes Ser-
530, no detectable modifications were observed (Figure 28). These results do not support covalent bond 
formation between the inhibitor and Ser-530.  
 
FIGURE 28. Peptide coverage of digested wild-type COX-2 following incubation with (S)-ARN2508. 
Peptide coverage of 84% was obtained from trypsin digestion of wild-type COX-2 following incubation 
with (S)-ARN2508. The peptide containing Ser-530 (PRPDAIFGETMVELGAPFSLK) was identified, but 
no mass shift of the peptide as would be expected from covalent modification by inhibitor was observed. 
 
 Although the data did not support covalent bond formation between the carbamoyl group of (S)-
ARN2508 and Ser-530 of COX-2, the crystal structure revealed the presence of a hydrogen bond between 
these moieties. To determine the importance of this interaction to ARN2508’s potency and to further rule 
out a covalent interaction, the ability of each enantiomer to inhibit a COX-2 S530A mutant enzyme was 
evaluated. As in the case of Y355F, the S530A mutation had minimal effect on enzymatic activity using 
AA as substrate. Furthermore, this mutation did not have a major effect on the potency of (S)-ARN2508 
and caused only a mild reduction in the potency of the (R)-enantiomer using AA as substrate and a 10 min 
preincubation (Figure 27). These findings do not support the hypothesis that an interaction (covalent or 
noncovalent) with the hydroxyl group of Ser-530 plays a significant role in ARN2508’s potency.  
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 Although the potency of (S)-ARN2508 (as measured by IC50 values) was nearly identical for wild-
type and S530A COX-2 following our standard 10 min preincubation time, the position of S530A at the 
bend of the active site suggested that this residue might interfere with the insertion of ARN2508’s 
hydrophobic tail into the upper part of the channel. To test this hypothesis, the rate of inhibition of the 
mutant to that of the wild-type enzyme at two concentrations of (S)-ARN2508 was compared (Figure 29A). 
The data clearly showed a much higher rate of inhibition in the case of the mutant enzyme. Unfortunately, 
the very rapid rates at high (S)-ARN2508 concentrations precluded a full kinetic analysis.  
 For a time-dependent inhibitor, the measured IC50 value is dependent on the length of the 
preincubation period. Longer preincubations provide time for the enzyme-inhibitor complex to form, 
making the inhibitor appear more potent and reducing the IC50. Consistently, when the potency of (S)-
ARN2508 was determined for S530A and wild-type COX-2 following a 30 s preincubation period, the IC50 
values obtained for both enzymes were substantially higher (0.31 µM for S530A and 4.51 µM for wild-
type) than those obtained following a 10 min preincubation. Notably, at this short preincubation time, (S)-
ARN2508 is significantly more potent against the mutant than the wild-type enzyme. This is due to the 
much more rapid development of inhibition with the mutant (Figure 30). 
 Since the S530A mutant decreases steric bulk from the bend in the COX-2 active site and eliminates 
hydrogen bonding with the inhibitor, we evaluated the effects of a COX-2 S530T mutation on inhibitor 
potency to observe how additional steric bulk in that region might alter the rate or potency of inhibition. 
This mutation had substantial effects on enzyme activity, both raising the KM (3-fold) and lowering the Vmax 
(3-fold). The mutation was also associated with a reduction in potency of (S)-ARN2508. Somewhat 
unexpectedly, however, the rate of inhibition of S530T observed with two concentrations of (S)-ARN2508 
was faster than that of the wild-type enzyme (Figure 29B). These results suggest that the larger threonine 
residue does not substantially impede the inhibitor’s access to the top channel of the COX-2 active site.  
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FIGURE 29. Kinetics of the time-dependent inhibition of S530A and S530T mCOX-2 by (S)-ARN2508. 
(A) Two concentrations of (S)-ARN2508 were incubated with wild-type or S530A mCOX-2 for the 
indicated preincubation times before the addition of 5 µM AA. Each enzymatic reaction proceeded for 10 
s before being quenched with organic solvent containing deuterated internal standards. Oxygenation of AA 
was assessed by quantification of enzymatic product formation utilizing LC-MS/MS. (B) Two 
concentrations of (S)-ARN2508 were incubated with wild-type or S530T mCOX-2 for the indicated 
preincubation times before the addition of 5 µM AA. Results are the mean ± S.D. of triplicate 
determinations.  
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FIGURE 30. Dose response of (S)-ARN2508 with 30 s preincubation. Indicated concentrations (S)-
ARN2508 were preincubated with either wild-type or S530A mCOX-2 for 30 s before the addition of 5 µM 
AA. Each enzymatic reaction proceeded for 10 s before being quenched with organic solvent containing 
deuterated internal standards. Oxygenation of AA was assessed by quantification of enzymatic product 
formation utilizing LC-MS/MS. Results are the mean ± S.D. of triplicate determinations. 
 
 
Inhibition of COX-2 Gly-533 mutants by (S)-ARN2508 
As observed from the crystal structure, AA binds in an L-shaped conformation with its omega tail 
inserted into the top channel of the COX-2 active site. Gly-533 lies near the end of the channel, and 
mutations of this residue to bulkier side chains inhibit the oxygenation of AA. However, Gly-533 mutants 
including G533A, G533V, and G533L can oxygenate the 18-carbon fatty acid a-LNA (46). One of the 
major products formed from this reaction is 12-hydroxy-octadecatrienoic acid (12-HOTrE) (58),  which 
contains a conjugated double bond that can be detected by UV-visible spectroscopy at 235 nm. The 
oxygenation of a-LNA by wild-type mCOX-2 and the mutant G533L in the presence of (S)-ARN2508 or 
(S)-flurbiprofen was evaluated to determine if disruption of the structure of the top channel would 
significantly impact ARN2508’s potency, due to the extension of the inhibitor’s hydrophobic tail to the end 
of the upper active site channel. Differences were observed between the wild-type enzyme and the G533L 
mutant with respect to inhibition by (S)-ARN2508 versus (S)-flurbiprofen. In Figure 31, oxygenation of a-
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LNA by wild-type mCOX-2 is shown to be completely inhibited by 10 µM of both (S)-ARN2508 and (S)-
flurbiprofen following a preincubation of 3 min or greater. With a 1 min preincubation, there was slight 
substrate oxygenation in the presence of (S)-ARN2508, but not (S)-flurbiprofen. In contrast, although (S)-
flurbiprofen completely inhibited mCOX-2 G533L following a 3 min preincubation, (S)-ARN2508 was 
only partially effective. Even following a 15 min preincubation, (S)-ARN2508 inhibited oxygenation by 
G533L COX-2 less efficiently than did (S)-flurbiprofen preincubated for just 1 min (Figure 31). These 
findings suggest that the bulky side chain of G533L interferes with the binding of (S)-ARN2508’s side 
chain in the active site channel and that this binding interaction is important to the inhibitor’s potency. 
 
FIGURE 31. Kinetics of LNA inhibition by (S)-ARN2508 and (S)-flurbiprofen. (A) Wild-type mCOX-2 
(200 nM monomer) with 30 nM of heme was used to oxygenate 50 µM LNA. 10 µM (S)-ARN2508 (ARN) 
or (S)-flurbiprofen (FB) from a DMSO stock were preincubated with enzyme for the indicated time before 
the addition of substrate. (B) G533L mCOX-2 (200 nM monomer) with 30 nM of heme was used to 
oxygenate 50 µM LNA. Reactions were monitored by increasing absorbance at 235 nm. 
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Discussion 
 
ARN2508 is a designed dual inhibitor of COX enzymes and FAAH. Herein, it was shown that each 
enantiomer of the compound exhibits distinct kinetics of inhibition of substrate oxygenation by both COX 
isoforms. (S)-ARN2508 is a time-dependent, highly potent, tightly bound inhibitor that is slightly more 
potent against COX-1 than COX-2. In contrast, (R)-ARN2508 is a weak, rapidly reversible inhibitor of AA 
oxygenation that is slightly more potent against COX-1 than COX-2 and a substrate-selective inhibitor for 
COX-2-dependent 2-AG oxygenation. This kinetic behavior of the two ARN2508 enantiomers is similar to 
that of the enantiomers of its parent compound, flurbiprofen (89,150-152).  
 The identical enantioselectivity of ARN2508 and flurbiprofen is not surprising, as the orientation 
of (S)-ARN2508’s flurbiprofen moiety in the COX-2 active site (Figure 23) is nearly identical to that 
observed for (S)-flurbiprofen in complex with COX-1 and COX-2. The a-methyl group of the flurbiprofen 
core of ARN2508 is adjacent to Tyr-355, which forms part of the constriction at the entrance into the active 
site. A similar binding interaction is observed for flurbiprofen, and previous studies have indicated that Tyr-
355 is involved in flurbiprofen’s time-dependent inhibition (80). A clash between Tyr-355 and the a-methyl 
group of the (R)-enantiomer of profen-class inhibitors has been predicted to interfere with binding, thus 
explaining the poor potency of these compounds (79). However, a crystal structure of (R)-flurbiprofen 
complexed with COX-2 revealed a shift in the inhibitor’s carboxylate group, α-carbon, and fluorophenyl 
ring that enables accommodation of the a-methyl group with retention of polar interactions with both Arg-
120 and Tyr-355. Nevertheless, the overall result is a reduction in total enzyme-inhibitor contacts that likely 
explains the (R)-enantiomer’s lower potency (89). It is likely that a similar conformational change is 
required to accommodate the (R)-methyl group of (R)-ARN2508, providing an explanation for its reduced 
potency relative to that of the (S)-enantiomer.  However, as a crystal structure of (R)-ARN2508 complexed 
with COX was not obtained, this hypothesis could not be confirmed. 
 Despite its structural and kinetic similarities to flurbiprofen, the alkyl carbamate substituent of 
ARN2508 imparts to it properties that are not observed in any other previously reported NSAID. These 
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include FAAH inhibition and utilization of the upper portion of the cyclooxygenase active site channel. 
Indeed, the crystal structure data reveal a number of interesting aspects to the binding interactions of 
ARN2508 in the active site of COX-2. The catalytic Tyr-385 residue forms hydrogen bonds with both 
oxygen atoms of the carbamate moiety of ARN2508 reminiscent of the hydrogen bond formed between 
Tyr-385 and the carbonyl oxygen of aspirin. This interaction places the aspirin carbonyl in a position that 
is hypothesized to be favorable for nucleophilic attack by the oxygen of Ser-530 and stabilizes the 
negatively charged tetrahedral intermediate formed in the transition state (70). However, in the COX-2•(S)-
ARN2508 complex crystal structure, an additional interaction is observed between the amide nitrogen of 
ARN2508 and Ser-530, thus making a nucleophilic attack by the Ser-530 hydroxyl group on the carbonyl 
carbon of the inhibitor less favorable. This is consistent with previous molecular modeling and simulation 
studies that predicted unfavorable geometry for covalent modification of COX by ARN2508 (153) and with 
site-directed mutagenesis data and tryptic peptide analysis by LC-MS/MS shown here, which do not support 
covalent modification of Ser-530 by the inhibitor. In fact, there is no major loss of (S)-ARN2508 potency 
for S530A COX-2, suggesting that the hydrogen bond between the inhibitor and Ser-530 also plays a 
minimal role in inhibitor potency. Nevertheless, the S530A mutation clearly exerts a subtle effect on the 
enzyme-inhibitor interaction. Specifically, (S)-ARN2508 inhibits the S530A mutant more rapidly than the 
wild-type enzyme.  
 Although slow-binding COX inhibitors have consistently been seen to exhibit multi-step kinetic 
mechanisms in which one or more rapidly reversible steps is/are followed by the rate-limiting formation of 
a much more tightly bound enzyme-inhibitor complex (84), the structural basis for the initial enzyme-
inhibitor interaction in most cases is poorly understood. For some NSAIDs, such as indomethacin and the 
diarylheterocycle class of COX-2-selective inhibitors, the slow step has been attributed to insertion of a 
portion of the molecule into a specific binding pocket in the enzyme active site (84). Such mechanistic data 
are not available for flurbiprofen or ARN2508. Clearly, however, the alkyl side chain of ARN2508 impacts 
its binding kinetics in that a longer preincubation period is required for (S)-ARN2508 than for (S)-
flurbiprofen to reach the same level of inhibition. Although kinetic analysis failed to clearly delineate the 
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mechanism of (S)-ARN2508-mediated inhibition of COX-2, the available data suggest that if a classic two-
step mechanism is applicable, much higher inhibitor concentrations are needed to form the initial complex 
for (S)-ARN2508 (KI ≈ 220 µM) than (S)-flurbiprofen (KI = 0.17 µM) (150). Alternatively, the (S)-
ARN2508-COX-2 complex may form in a single slow step or in multiple steps of which the first one is 
rate-limiting. The only structural difference between flurbiprofen and ARN2508 is the presence of the alkyl 
carbamate side chain on the latter. Thus, it is reasonable to hypothesize that insertion of ARN2508’s alkyl 
chain into its position in the active site is responsible for their kinetic differences. Our data also support the 
hypothesis that Ser-530, which is present at the bend of the channel plays a role in the insertion process. 
Mutation of Ser-530 to Ala shortens the time required for (S)-ARN2508 to inhibit COX-2, whereas it does 
not affect the rate of binding of flurbiprofen. Hydrogen bond interactions between Ser-530 and the 
carbamoyl group of the inhibitor may also contribute to its COX-2 binding interaction, although removal 
of this hydrogen bond does not substantially alter potency as measured in our standard IC50 assay.  
 To further investigate the effects of Ser-530, we mutated it to a bulkier threonine residue. This 
mutation resulted in a 90% reduction in catalytic efficiency (kcat/KM), suggesting that the added bulk 
significantly impairs active site structure and/or dynamics. It also resulted in a mild reduction in potency of 
(S)-ARN2508 although the rate of inhibition was, surprisingly, slightly higher than that of the wild-type 
enzyme (Figure 29A). Structural studies have shown that the threonine side chain of the mutant overlays 
one of several alternative conformations adopted by serine in the wild-type enzyme (154). This orientation 
must provide sufficient room for the w-end of the substrate to access the hydrophobic top channel. The 
hydroxyl group of threonine can also hydrogen bond to the inhibitor, as does that of the serine residue, 
based on an assessment of the previously deposited S530T crystal structure. 
 Our data suggest substantial importance of the nonpolar interactions established between the alkyl 
chain of ARN2508 and the top channel of COX-2, which is lined with hydrophobic residues. This region 
of the active site, where the w-tail of AA normally binds, has not previously been reported as the site of a 
COX protein-inhibitor interaction. The interactions observed in our crystal structure are consistent with 
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previous structure-activity relationship (SAR) studies (155), and in accordance with those predicted by 
molecular simulations that showed a nearly identical statistical distribution of hydrophobic contacts 
between COX-1 and AA when compared to COX-1 and ARN2508 (153). In the SAR studies, increasing 
the length of the alkyl chain up to eight carbons correlated with an increase in potency toward FAAH. 
However, the trend differed with respect to inhibition of COX-1 and COX-2. Short alkyl chains with two 
or three carbons exhibited low inhibitor potency. Increasing chain length resulted in an increase, followed 
by a decrease in potency for both isoforms. Inhibition of COX-1 was maximized at a chain length of six 
carbons, whereas that for COX-2 was optimal and similar for chain lengths of five to seven carbons. The 
current crystal structure revealed that the additional steric bulk of longer alkyl chains cannot be 
accommodated in the hydrophobic channel. Kinetic experiments with the G533L mutant of COX-2 further 
support the hypothesis that the alkyl chain of ARN2508 binds in the top channel and that this interaction is 
important to inhibitory kinetics in a way that is specific to ARN2508. In particular, a G533L mutation 
markedly reduces the potency of ARN2508 while having little effect on the potency of flurbiprofen. 
Mutation of this residue to valine is known to abolish oxygenation of AA due to the inability of the substrate 
to access the top channel and bind close enough to Tyr-385 to initiate the enzymatic reaction (156). 
 
Conclusions 
 COX-2 and FAAH are critical enzymes in the inflammatory response; they regulate the presence 
of pro-inflammatory eicosanoids and degrade endocannabinoids that have analgesic and anti-inflammatory 
effects. ARN2508 is a pharmacologically distinctive compound in that it can simultaneously block the 
activity of both enzymes. Here, it was shown that the in vitro efficacy of ARN2508 for inhibition of PG 
synthesis is primarily attributable to the (S)-enantiomer, whereas both enantiomers may effectively block 
COX-2-dependent oxygenation of endocannabinoids. In contrast, ARN2508-mediated inhibition of FAAH 
is not affected by the orientation of the compound’s a-methyl group. Rather, ARN2508 irreversibly blocks 
FAAH through covalent modification of the enzyme via a reaction between the carbamate moiety of the 
inhibitor and the catalytic Ser-241 of FAAH (157). Here, it is also shown that a covalent modification of 
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COX-2 by ARN2508 does not occur based on crystal structure, site-directed mutagenesis, and analysis of 
digested peptides by mass spectrometry. Although their mechanisms of inhibition differ, FAAH and COX 
enzymes both contain long, hydrophobic channels, allowing favorable binding of ARN2508 (158). In 
conclusion, ARN2508 inhibits COX via structural determinants contributed primarily by its flurbiprofen 
moiety, whereas the alkyl carbamate substituent, which is required for FAAH inhibition, imparts distinct 
attributes to its COX inhibitor kinetics and binding interactions. 
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CHAPTER V 
 
 
EFFORTS TOWARD INVESTIGATING THE STRUCTURAL DYNAMICS OF 
CYCLOOXYGENASE-2 WITH CRYO ELECTRON MICROSCOPY 
 
 
 Multiple X-ray crystal structures of COX-2 in complex with various substrates and inhibitors have 
been deposited in the PDB. Although these structures have provided invaluable insight into the structural 
characteristics of the enzyme, X-ray crystallography is limited as a biophysical technique since it gives a 
more static snapshot of a molecule bound in a particular conformation to a protein. Since COX-2 is a 
membrane-bound enzyme, it must be initially solubilized in detergent for crystallization. Therefore, the 
conformational dynamics of the enzyme in a detergent solution might differ from its native membrane 
environment. In recent years, Cryo-electron microscopy (Cryo-EM) has improved significantly in its 
capability to determine the molecular structures of larger proteins and protein complexes at high resolution. 
This is due, in part, to the utilization and improvement of the direct electron detector and advancements in 
image processing (159). Cryo-EM is advantageous in that protein structures can be studied in their native 
or nearly native environment (160). Cryo-EM data analysis of a protein can also be combined with X-ray 
structures for initial modeling to generate valuable biophysical information.    
Nanodiscs are lipid bilayer mimetics which have gained significant utilization in recent years for 
various biochemical studies. Nanodiscs consist of a bilayer of synthetic phospholipids encircled by variants 
of the apolipoprotein A1, also known as membrane-scaffold proteins (MSPs). Within the assembled 
phospholipid bilayer, membrane proteins with TM helices can embed or membrane binding domains can 
attach to the phospholipid head groups, similarly to their assembly in a native membrane bilayer (161). 
COX-2 has been reconstituted into nanodiscs to assess its biochemical function and negative stain EM 
confirmed that a single homodimer of COX-2 associated with one leaflet of a single nanodisc (162). To 
further assess the structural dynamics of COX-2, recombinant purified enzyme was reconstituted into 
nanodiscs and investigated using Cryo-EM in collaboration with the laboratory of Hans Hebert at the 
Karolinska Institutet in Huddinge, Sweden.  
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Results 
 To prepare the COX-2-containing nanodiscs, recombinant His6-tagged enzyme was mixed with an 
excess of POPC phospholipids and MSP1E3D1 scaffold protein. The components were mixed at 4 °C for 
at least one hour. Hydrophobic Bio-beads were added to the reaction mixture to absorb detergent from the 
solution and initiate the self-assembly of the nanodiscs. The mixtures were stirred overnight and purified 
with size-exclusion chromatography. Following purification, fractions were assessed for their purity by 
SDS-PAGE. In Figure 32, it can be seen that two prominent bands are present from each fraction, as 
expected. The top band corresponds to a molecular weight of approximately 72 kDa, representing a 
monomer of COX-2. The bottom band corresponds to a molecular weight of approximately 30 kDa, 
representing the non-tagged MSP1E3D1 scaffold protein. The intensity of the MSP band is greater than 
that of COX-2, most likely indicative of excess nanodiscs. 
 
Figure 32. SDS-PAGE gel of COX-2 reconstituted nanodiscs with an excess of empty nanodiscs. 
 
To initially assess the assembled nanodiscs, negative stain EM was utilized. This technique relies on a 
heavy metal contrasting agent to enable the visualization of protein particles by the electron microscope. 
Following the purification of COX-2 reconstituted nanodiscs using size-exclusion chromatography, an 
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aliquot was diluted to a final total protein concentration of approximately 300 ng/mL. 3 µL of the solution 
was added to a glow-discharged carbon-coated copper grid. 3 µL of a buffer containing 1% uranyl formate 
was subsequently added to the grid and analysis of the sample was completed using a transmission electron 
microscope at room temperature. Upon the investigation of the particles, most appeared to be uniform in 
shape, resembling empty nanodiscs (Figure 33).  
 
Figure 33. Negative stain EM of COX-2 reconstituted nanodiscs following size-exclusion chromatography. 
Larger, dark circles are stain contaminants, whereas smaller light circles represent nanodisc particles. An 
excess of empty nanodiscs was present after initial purification. 
 
An additional COX-2 nanodisc preparation was completed utilizing an additional IMAC purification step 
before the final size-exclusion purification step. Again, purified COX-2 was mixed with an excess of POPC 
phospholipids and detergent was removed from the solution with the addition of Bio-beads. Following the 
self-assembly of the nanodiscs, the sample was buffer exchanged to remove excess EDTA in solution, 
which can affect IMAC purification. The sample was then incubated with Ni-NTA resin for at least one 
hour at 4 °C. Empty nanodiscs with the non-tagged MSP were washed from the resin with a similar buffer 
0.2 µm
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containing 50 mM imidazole. His6-tagged COX-2 reconstituted into nanodiscs was eluted from the resin 
with a similar buffer containing 200 mM imidazole. Fractions including the flow-through, wash, and elution 
were collected and analyzed by SDS-PAGE. A majority of the excess empty nanodiscs did not bind to the 
resin and were found in the flow-through fraction, as well as the first wash fraction. Additional wash 
fractions contained very small amounts of protein. The elution fraction displayed both expected bands from 
COX-2 and the MSP. Therefore, the elution fraction contained purified nanodiscs containing COX-2 
(Figure 34). 
 
Figure 34. SDS-PAGE gel of purified COX-2 reconstituted nanodiscs following IMAC and size-exclusion 
purifications. Lanes from left to right: 1: Flow-through. 2: Wash 1. 3: Wash 2. 4: Wash 3. 5: Elution 1. 6: 
MW marker. 
 
To further assess the incorporation of COX-2 into the nanodisc bilayer, a Native PAGE gel was utilized to 
observe the migration of the nanodisc complex under non-denaturing conditions. For the native gel, 1 µg 
of total protein in each sample was loaded and analyzed with Coomassie blue staining. One sample 
contained recombinant COX-2 solubilized in detergent, another sample contained empty nanodiscs, and the 
final sample contained COX-2 reconstituted nanodisc complexes. The native gel revealed a sharp band for 
detergent-solubilized COX-2. However, nanodisc samples exhibited smearing in the gel due to an excess 
of phospholipids. A shift can be observed between the empty nanodisc sample to a higher molecular weight 
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in the sample consisting of the COX-2 nanodisc complex. The approximate molecular weight of the 
complex based on the molecular weight marker was approximately 400 kDa, thus indicating the 
incorporation of one COX-2 dimer into one leaflet of a single nanodisc (Figure 35). 
 
Figure 35. Native PAGE gel of COX-2 nanodiscs. 1 µg of total protein was loaded in each sample. Samples 
from left to right include: 1: Detergent-solubilized COX-2. 2: Empty POPC nanodiscs. 3: COX-2 nanodiscs. 
4: MW Marker. 
 
Following the purification of COX-2 nanodiscs with both IMAC and size-exclusion purification, samples 
were initially assessed with negative stain EM. The nanodisc sample following the final purification was 
diluted to a concentration of approximately 7 µg/mL, added to a carbon grid as described above, and 
analyzed with the electron microscope. Upon analysis, it was observed that the particles were more irregular 
in shape, indicating that a majority of the particles were nanodiscs containing COX-2 (Figure 36). 
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Figure 36. Negative stain EM of COX-2 reconstituted nanodiscs following IMAC and size-exclusion 
chromatography. Particles are indicative of COX-2 reconstituted nanodisc complexes. 
 
Cryo-EM was subsequently utilized to assess the COX-2 nanodiscs following negative stain EM. Similarly 
to negative stain, the COX-2 nanodisc sample was diluted to either approximately 35 µg/mL or 14 µg/mL 
and a 3 µL aliquot was added to a glow-discharged Quantifoil holey carbon grid. Grids were plunge-frozen 
in liquid ethane and subsequently stored frozen in liquid nitrogen. The initial dataset from Cryo EM analysis 
consisted of 244 images and 65,164 particles. 2D class averages were calculated from a smaller set of 
particles to assess the quality of the data set. The two-fold symmetry of the COX-2 dimer can be clearly 
distinguished in many of the image averages (Figure 37). 
0.2 µm
 87 
 
Figure 37. 2D class averages of COX-2 nanodisc particles from Cryo-EM. Each class average box 
measures approximately 238 Å2 (23.8 nm2). 
 
The atomic structure of AA bound to the COX-2 active site (PDB: 3HS5)(48) was low-pass filtered to 60 
Å and used to generate an initial model for 3D refinement (Figure 38).  
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Figure 38. 3D model of electron density from COX-2 nanodiscs generated based on the atomic structure 
of AA bound to COX-2 (PDB: 3HS5). 
 
 
Discussion 
 The reconstitution of recombinant wild-type mCOX-2 into nanodics was successfully completed. 
The initial nanodiscs were produced exclusively utilizing POPC phospholipids. The formed nanodiscs were 
purified with size-exclusion chromatography. Since an excess of phospholipids and MSP was added relative 
to COX-2, an excess of empty nanodiscs were formed. Unfortunately, size-exclusion chromatography was 
not efficient at separating the empty nanodiscs from the COX-2:nanodisc complexes. Therefore, initial 
investigation with negative stain EM revealed that a majority of the empty nanodiscs were, in fact, present 
in the solution.  
 The next nanodisc preparation proceeded similarly but was followed with an additional IMAC 
purification step, utilizing the His6-tag of COX-2. Again, an excess of POPC phospholipids and MSP were 
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added relative to the COX-2 dimer for preparation of the nanodiscs. The mixture was incubated with Ni-
NTA resin in order to separate the COX-2-reconstituted nanodiscs and empty nanodiscs. Analysis with 
SDS-PAGE indicated that a majority of the empty nanodiscs did not bind to the resin and were found in the 
flow-through. The COX-2-reconstituted nanodiscs were eluted from the resin with a high imidazole 
concentration and subsequently purified with size-exclusion chromatography. Following purification, the 
COX-2:nanodisc sample was analyzed with negative stain EM, revealing particles which contrasted those 
from the initial nanodisc preparation. A majority of the particles were observed to be more irregular in 
shape, whereas the initial preparation produced more uniformly circular particles. Thus, the additional 
IMAC purification was sufficient for yielding COX-2 reconstituted into POPC nanodiscs that could be 
identified with EM. 
 The COX-2:nanodisc solution was further diluted to approximately 35 µg/mL and investigated 
using Cryo-EM. Multiple images were collected and averaged into multiple 2D images. In many of the 2D 
class averages, the two-fold symmetry of the COX-2 dimer can be observed, including less electron density 
at the dimer interface. The electron density was modeled into three dimensions using the X-ray crystal 
structure of COX-2 with AA in the active site (PDB: 3HS5) and clearly overlapped most of the residues. 
Unfortunately, most of the electron density of the nanodisc could not be observed from the initial 3D model, 
most likely due to increased molecular motion relative to the more static COX-2 dimer. 
 
Conclusions 
 The work presented here showed that recombinant COX-2 can be reconstituted into nanodiscs and 
analyzed with EM. Although electron density of the COX-2 dimer was seen in the reconstructed 3D model, 
resolution was relatively low and most of the electron density from the nanodisc components was absent. 
Future experiments will optimize buffer conditions as well as the incorporation of alternative phospholipids 
in the nanodisc bilayer. In addition to POPC, other phospholipids such as phosphatidylserine (PS) or PI can 
be incorporated into the nanodisc complex to more closely mimic the cellular membrane bilayer 
composition. 
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CHAPTER VI 
 
 
ELUCIDATION OF THE CHEMICAL MECHANISM OF HUMAN INDUCIBLE MICROSOMAL 
PROSTAGLANDIN E2 SYNTHASE 1 
 
 
 
 In 2013, a high-resolution crystal structure of recombinant human mPGES-1 was solved and 
revealed that a Ser-127 residue was in close proximity to the thiolate of the GSH cofactor in the active site 
(123). Asp-49 and Arg-126 are additional residues in the active site and were proposed to be essential for 
catalysis. Although a chemical mechanism for the mPGES-1 reaction was proposed based on these 
structural data, it was not confirmed with site-directed mutagenesis activity assay studies. In this work, 
projects were completed in collaboration with laboratories at the Karolinska Institutet in Stockholm, 
Sweden to further elucidate the catalytic mechanism of mPGES-1 and if other GSH analogues are sufficient 
for substrate isomerization.  
 
Results 
 
 
Protein expression and purification optimization in Sf9 cells 
 
 In order to complete initial kinetic and inhibitory studies, recombinant human mPGES-1 enzyme 
was overexpressed in an E. coli system. Typically, approximately 500 µg of purified enzyme was obtained 
from 9 liters of cell culture. The low enzyme yield was not sustainable for multiple kinetic assays, especially 
when larger volumes of concentrated enzyme are required for stopped-flow spectroscopy studies. To 
increase the yield of recombinant enzyme, a baculovirus expression system was utilized. Amplified 
baculovirus stocks containing the human mPGES-1 gene were used to infect large cultures of Spodoptera 
frugiperda Sf9 cells and cultured for overexpression of the enzyme. Typically, from 2 liters of cell culture, 
approximately 2.5 mg of purified enzyme was obtained following protein expression and purification. 
Utilizing purification with IMAC, cation-exchange, and size-exclusion chromatography, homogeneously 
folded enzyme was obtained with a purity of ³ 95% (Figure 39).  
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Figure 39. SDS-PAGE gel of wild-type human mPGES-1. 
 
Glutathione Transferase Assay  
 Following recombinant mPGES-1 purification, enzyme activity was initially assessed by observing 
the conjugation of GSH to CDNB. mPGES-1 was reported to catalyze this reaction, although it is much 
less efficient than other MAPEG proteins such as MGST1. The specific activity of this reaction at 30 °C 
was reported to be 0.8 µmol min-1 mg-1 (116). For the assay reported here, reactions were performed at room 
temperature, and specific activity was slightly lower than but comparable to the literature value, at 0.6 µmol 
min-1 mg-1 (Figure 40). 
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Figure 40. GST activity assay in the presence of wild-type mPGES-1. 
 
mPGES-1 activity with glutathione analogues 
 Based on previously reported structural and kinetic data, it was known that GSH is a required 
cofactor for the isomerization of PGH2 by mPGES-1. To initiate catalysis, the thiolate of GSH is activated, 
enabling it to exert a nucleophilic attack on the oxygen of carbon-9 of the cyclopentane ring, forming a 
sulfenic acid ester intermediate (126). Nucleophilic attack by an activated thiolate is a common mechanism 
for initiating catalysis by other MAPEG proteins as well as GSTs. In fact, the isozymes 3-3 and 4-4 of rat 
liver GST were inhibited by two GSH analogues, including the replacement of the more reactive thiol with 
a hydroxyl group in the serine analogue (GOH) or substitution of the thiol with a methyl group in the alanine 
analogue (GH). These analogues are competitive inhibitors of GSH in the presence of varying 
concentrations of the CDNB substrate (142). Both the serine and alanine analogues of GSH were 
synthesized and utilized to investigate the activity of purified mPGES-1. The purity of each analogue was 
verified with 1H-NMR (Figure 41) as well as 13C-NMR. Chemical shifts corresponded to the reported 
literature values.  
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Figure 41. 1H-NMR spectra of the oxygen analogue γ-L-Glu-L-SerGly (GOH) and the desthio analogue of 
glutathione, γ-L-Glu-AlaGly (GH). 
 
 
The enzymatic activity of mPGES-1 purified in the presence of 1 mM GSH was compared with that of 
mPGES-1 purified in the presence of 1 mM GOH or GH and to the spontaneous reactions with either 1 mM 
GSH, GOH, or GH. For each enzymatic reaction (mPGES-1-GSH, mPGES-1-GOH, mPGES-1-GH), 1 mM 
of the corresponding cofactor was added to the reaction buffer, in addition to the enzyme-cofactor complex, 
and the isomerization of 25 µM PGH2 to PGE2 was observed by LC-MS/MS. The amount of PGE2 was 
quantified from its peak area in each chromatogram relative to the peak area of the internal standard 11b-
PGE2. In Figure 42, it can be observed that approximately 5-10% of PGH2 spontaneously isomerized to 
PGE2 in the presence of 1 mM GSH, GOH, or GH and the absence of any enzyme (red bars). This result is 
not surprising, as PGH2 is unstable in aqueous buffer, isomerizing to both PGE2 and PGD2. In the presence 
of 100 nM wild-type mPGES-1 purified in the presence of 1 mM GSH and 1 mM added GSH, 
approximately 30% of PGH2 substrate was isomerized to PGE2 in a 1 min reaction. However, the same 
reaction in the presence of wild-type mPGES-1 purified in the presence of either 1 mM GOH or 1 mM GH 
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plus 1mM of added GOH or GH, respectively, had comparable substrate isomerization to those of the 
corresponding the spontaneous reactions, thus indicating that GSH is an essential cofactor, and the activated 
thiolate is crucial for catalysis. 
 
Figure 42. PGH2 isomerization with GSH, GOH, and GH. The formation of the PGE2 product was 
quantified by LC-MS/MS and quantified relative to the internal standard, 11b-PGE2. 
 
To further investigate the activity of enzyme in complex with the GOH analogue, experiments were 
performed to see if varying concentrations of exogenously provided GOH could compete with GSH for 
binding to the enzyme and subsequently inhibit isomerization. Moreover, experiments were performed to 
see if GSH could compete with GOH for binding to the enzyme and rescue substrate isomerization. In 
Figure 43, the enzymatic isomerization of PGH2 is represented by the blue bar. For this particular condition, 
100 nM wild-type mPGES-1 purified with 1 mM GSH, plus 1mM of added GSH, and no GOH analogue, 
catalyzed substrate isomerization. The green bars represent the same reaction conditions with 100 nM 
enzyme and 1 mM GSH, but with increasing concentrations of GOH. Even up to a concentration of 10 mM 
GOH, a significant reduction in substrate isomerization was not observed. An opposite effect was observed 
when 100 nM wild-type mPGES-1 purified with 1 mM GOH, plus 1mM of added GOH, and no GSH was 
utilized for catalysis. As seen in Figure 44, substrate isomerization with only GOH was comparable to 
spontaneous isomerization. However, the addition of 0.5 mM GSH to the reaction mixture was able to 
completely rescue substrate isomerization. 
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Figure 43. PGH2 isomerization with GSH and competition with increasing concentrations of GOH. The 
formation of the PGE2 product was quantified by LC-MS/MS. 
 
 
 
Figure 44. PGH2 isomerization with GOH and competition with increasing concentrations of GSH. The 
formation of the PGE2 product was quantified by LC-MS/MS. 
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Similar results were observed for PGH2 isomerization in the presence of mPGES-1 purified with GOH in 
collaborative experiments performed by the laboratory of Jesper Haeggström at the Karolinska Institutet 
(126). 
 
Stopped-flow kinetics of mPGES-1 thiolate formation 
 Stopped-flow is a spectroscopic technique used for investigating rapid reaction mechanisms in a 
solution over the course of about 1 millisecond to hundreds of seconds. The change in the fluorescence 
signal or absorbance at a particular wavelength can then be recorded as a function of time. Assuming that 
one-third the sites of the mPGES-1 trimer contain an activated thiolate at one time, one equivalent of the 
thiolate of GSH can be observed by difference spectroscopy since thiolates have an absorption band at 239 
nm (ε239 = 5000 M-1 cm-1). The mPGES-1-GSH complex was mixed rapidly with GOH to observe if there 
was a loss of the absorbance at 239 nm. Initially, 50 µM of wild-type mPGES-1 in complex with GSH was 
mixed with 20 mM GOH in a stopped-flow cell, giving final concentrations of 25 µM and 10 mM, 
respectively. The absorbance at 239 nm was recorded for up to 300 s. A distinct change in absorbance at 
239 nm could not be observed (Figure 45A).  
 
Figure 45. (A) Stopped-flow chromatogram monitoring absorbance at 239 nm with 25 µM mPGES-1 and 
10 mM GOH. (B) Stopped-flow chromatogram monitoring absorbance at 239 nm with 150 µM mPGES-1 
and 10 mM GOH. 
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Therefore, the enzyme was concentrated to approximately 300 µM and injected into the stopped-flow cell 
against 20 mM GOH. The overall absorbance was increased, but an expected change in absorbance at 239 
nm corresponding to the transient loss of the thiolate was not observed (Figure 45B). Similar experiments 
were also performed the mPGES-1-GSH complex was mixed rapidly with GSO3- but an observable change 
in absorbance at 239 nm was not detected (data not shown). 
 
mPGES-1 Peptide Mapping by Mass Spectrometry 
 The conformational dynamics of proteins can be monitored with HDX-MS more effectively than 
with other biophysical techniques such as X-ray crystallography, which gives a more static snapshot of the 
structural components. HDX-MS revealed that the competitive inhibitor GSO3- causes changes in the 
structure of mPGES-1 due to the presence of additional electron density from the oxygen atoms of the 
sulfonate group (138). With the replacement of GSH with GOH or GH, structural dynamics are likely to be 
unchanged, but this can be verified with HDX-MS. In order to investigate mPGES-1 conformational 
dynamics using HDX-MS, it was necessary to initially map the peptide elution patterns using LC-MS/MS. 
mPGES-1 storage buffer was optimized to include the minimum amount of salts, glycerol, and detergent in 
order to keep the enzyme stable, yet minimally suppress the ionization signal from the mass spectrometer. 
Various experimental parameters, including mobile phase gradients, enzyme concentrations, and pepsin 
concentrations and incubation times, were initially optimized to give the most complete peptide coverage 
of the enzyme. The mPGES-1 enzyme in complex with GSH was mapped with approximately 83% of 
peptide sequences identified in the proteomics software PEAKS 7. After verifying the fragmentation 
patterns of these peptides, approximately 81% of peptide sequences were successfully confirmed and 
mapped (Figure 46). Many of the amino acid residues that have been proposed to form hydrogen bonds 
with the GSH cofactor were identified and mapped. Although peptides of mPGES-1 were sufficiently 
mapped, subsequent HDX-MS studies with the enzyme in complex with each analogue were not completed 
due to the transition of laboratories and initiating projects with COX-2. 
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Figure 46. Confirmed peptide coverage of mPGES-1 using LC-MS/MS. Blue indicates peptide coverage 
and red indicates no peptide coverage. 
 
 
Role of Serine 127 in mPGES-1 Catalysis 
 Ser-127 of mPGES-1 was proposed to act as a hydrogen bond donor to stabilize and activate the 
thiolate of GSH, thus enabling nucleophilic attach on PGH2 (123). Site-directed mutagenesis of Ser-127 as 
well as other possible residues involved in the catalytic mechanism, Asp-49 and Arg-126, was not 
completed along with the structural analysis. To further investigate the proposed chemical mechanism, Asp-
49, Arg-126, and Ser-127 mutant sequences were separately prepared by site-directed mutagenesis of the 
wild-type recombinant mPGES-1 gene sequence in the baculovirus transfer vector. Initially, the Ser-127-
Ala mutant was expressed and purified in Sf9 cells and used to assess the isomerization of PGH2. 
Unexpectedly, the isomerization of PGH2 in the presence of 100 nM Ser-127-Ala mPGES-1 was 
comparable to that of the wild-type control (Figure 47).  
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Figure 47. PGH2 isomerization in the presence of wild-type and S127A mPGES-1. The formation of the 
PGE2 product was quantified by LC-MS/MS. 
 
As previously mentioned, GSO3- acts a competitive inhibitor which cannot initiate catalysis due to the lack 
of the nucleophilic thiolate. Moreover, the additional electron density from the sulfonate oxygens alters the 
conformation of the mPGES-1 active site. Since Ser-127 is approximately 3.2 Å from the thiol of GSH in 
the mPGES-1 active site, additional steric bulk at that position could possibly disrupt catalysis. Therefore, 
Ser-127 was mutated to a residue with an additional electron shell. The Ser-127-Cys mutation was 
expressed and purified similarly to the wild-type and S127A enzymes. The isomerization of PGH2 to PGE2 
in the presence of the S127C was initially observed by fluorescence (Figure 48) and additionally by mass 
spectrometry (Figure 49). Based on 1 min reaction times with 100 nM enzyme, a significant reduction in 
activity was observed for the S127C mutant as compared to both the wild-type and S127A enzymes. 
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Figure 48. MDA fluorescence assay to assess the activity of wild-type, S127A, and S127C mPGES-1 
enzymes. Fluorescence was observed for the MDA-TBA complex, formed from the degradation of 
unreacted PGH2 substrate. 
 
 
 
 
Figure 49. PGH2 isomerization to assess the activity of S127A and S127C mPGES-1 enzymes in the 
presence of 1 mM GSH. The formation of the PGE2 product was quantified by LC-MS/MS. 
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An additional assay investigated the isomerization of PGH2 in the presence of Ser-127-Cys mPGES-1 
purified in the presence of 1 mM GSH or 1 mM GSO3- in order to determine if the cysteine residue could 
potentially function as a nucleophile and initiate catalysis in the active site. However, mPGES-1 Ser-127-
Cys purified with GSO3- had comparable activity to the spontaneous reaction and lower than that of 
mPGES-1 Ser-127-Cys purified with GSH (Figure 50). 
 
 
Figure 50. PGH2 isomerization to assess the activity of 100 nM mPGES-1 S127C purified with either 
GSH or purified with 1 mM GSO3-. The formation of the PGE2 product was quantified by LC-MS/MS. 
 
Discussion 
 
mPGES-1 activity with glutathione analogues 
 GSH analogues including the oxygen analogue (GOH) and the desthio analogue (GH) were 
previously shown to be inhibitors of two isozymes of GST from rat liver (142). Both of these analogues 
were synthesized and used to assess if they could promote the mPGES-1-catalyzed isomerization of PGH2. 
GSH is a cofactor that is crucial for mPGES-1 enzyme activity and structural stability. GSH hydrogen bonds 
to amino acid residues from two individual subunits of the mPGES-1 trimer, forming part of the active site 
in the cavity between them. Although GSH is known to bind between the subunit interfaces of the enzyme, 
less is known about the binding affinity of GSH in all three subunits at any given time. However, molecular 
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dynamic simulations and hybridization experiments suggested that the enzyme exhibits one-third-sites 
reactivity (124). Since GSH is known to catalyze substrate isomerization, both GOH and GH analogues 
were separately purified with mPGES-1 to investigate their effects on enzyme activity. As expected, the 
rate of substrate isomerization by the enzyme purified with the desthio analogue (GH) was comparable to 
that of the spontaneous reaction. This was not a surprising result, as a nucleophilic compound is needed to 
initiate catalysis. A similar absence of catalytic activity was observed in the case of mPGES-1 complexed 
with GOH indicating that its nucleophilic hydroxyl group lacks sufficient reactivity to catalyze the 
isomerization reaction. Since both analogues failed to substitute for GSH to form active mPGES-1, a 
competition experiment was completed to investigate whether the GOH analogue could displace GSH in 
the active site and inhibit activity or if GSH could displace GOH and thus rescue activity. Surprisingly, 
GOH was unable to significantly inhibit mPGES-1 activity in complex with GSH, even when 10 mM GOH 
was added to the reaction. This finding contrasts with results of earlier experiments with GSO3-, a known 
competitive inhibitor of mPGES-1 with an IC50 value of 1.8 mM (138). Note that, for assessing GSO3--
mediated inhibition, the final concentration of GSH in each reaction was 0.4 mM. The KM of GSH for 
mPGES-1 is 0.71 mM (116). In the studies reported here, a final GSH concentration of 1 mM was used, so 
one would expect higher concentrations of competitor to be required to observe inhibition. However, the 
absence of significant effect at a GOH/GSH ratio of 10:1 suggests that the affinity of GOH for the enzyme 
is much lower than that of GSH. In a similar assay, mPGES-1 purified with GOH was added to reaction 
mixtures containing a final GOH concentration of 1 mM. In the absence of any GSH, no activity was 
observed. However, adding only 0.5 mM GSH was sufficient to completely rescue enzymatic activity. This 
result was rather surprising as GSH and GOH are structurally similar, yet it appears that mPGES-1 has a 
strong preference for GSH binding in the active site.  
Stopped-flow kinetic experiments were utilized to spectroscopically detect the thiolate from 
mPGES-1 complexed with GSH.  One equivalent of the thiolate of GSH, based on one-third of sites 
occupancy, can be observed by difference spectroscopy from the thiolate absorption band at 239 nm. Since 
the mPGES-1 enzyme is unstable in the absence of GSH, simple difference spectroscopy experiments using 
 103 
the apo-enzyme are not possible. The loss of the absorbance at 239 nm will correlate with the replacement 
of the GSH thiolate and indicate its rate of dissociation from the enzyme. Based on the observed first-order 
rate constant, it can be determined whether or not GSH is bound tightly to the enzyme. To determine if the 
sulfenic acid ester intermediate is present in the chemical mechanism of mPGES-1, stopped-flow 
spectroscopy experiments can also be utilized. If the proposed intermediate were indeed formed, it would 
result in the transient loss of the thiolate signal at 239 nm immediately followed by a recovery of the signal 
if the formation of the intermediate is faster than its decomposition. For a 25 µM enzyme solution in the 
stopped-flow cell, the expected absorbance for the thiolate at 239 nm would be approximately 0.125. That 
absorbance would be lowered to approximately 0.04, assuming that one-third of the trimer interfaces 
contain a thiolate at one time, as was observed for the structurally related enzyme, MGST2 (109). In the 
experiments completed here, the change in absorbance was only approximately 0.01 for the 25 µM enzyme 
injection, much weaker than expected for the replacement of the thiolate in the active site. Similar results 
were also observed when 25 µM enzyme was injected against GSO3-. When the enzyme concentration was 
increased to 150 µM in the stopped-flow cell, an absorbance change of approximately 0.25 was expected. 
However, no observable change in absorbance corresponding to the loss of the thiolate occurred after the 
enzyme was rapidly mixed against GOH. Further optimization of the stopped-flow experiments is necessary 
to observe the potential thiolate signal in the presence of mPGES-1. Moreover, further kinetic studies in 
addition to structural dynamic investigations with HDX-MS would be needed to assess the enzyme’s 
preference in binding GSH in its active site. The presence of either GOH or GH bound to the enzyme could 
cause the solvent accessibility for active site peptides to be different compared to solvent accessibility when 
the enzyme is bound to GSH. The differences would likely be minimal since the hydroxyl of GOH and the 
methyl of GH occupy smaller areas compared to the thiol of GSH. 
 
Role of Serine 127 in mPGES-1 Catalysis 
 mPGES-1 mutants, including Asp-49-Ala, Arg-126-Ala, Ser-127-Ala, and Ser-127-Cys, were 
prepared by mutating the wild-type mPGES-1 gene sequence in a baculovirus transfer vector. Initially, the 
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Ser-127-Ala mutant enzyme was tested for its ability to isomerize PGH2 in the presence of GSH. 
Surprisingly, the enzymatic activity of the mutant was comparable to that of the wild-type enzyme. An 
additional mutant, Ser-127-Cys, interestingly showed decreased enzyme activity compared to that of the 
wild-type control. Since the thiol of Cys possesses a larger electron radius compared to the hydroxyl of Ser, 
this result suggested that it might disrupt the conformation of the GSH thiolate in the active site. Therefore, 
catalysis is still possible, but its rate might be impaired by a reduced rate of substrate binding into or product 
exit from the active site. An additional assay tested the activity of the Ser-127-Cys mutant in the presence 
of the GSO3- inhibitor. The Ser-127-Cys mutant complexed with GSO3- could presumably catalyze substrate 
isomerization by a nucleophilic attack exerted by the Cys thiol. However, isomerization in the presence of 
the mutant and GSO3- was comparable to spontaneous isomerization, thus indicating a Cys thiol in the 
mPGES-1 active site cannot act as a nucleophile to initiate catalysis. It is also possible that GSO3- inhibits 
substrate binding to Ser-127-Cys mPGES-1. Therefore, additional experiments investigating substrate 
isomerization with Ser-127-Cys purified in the presence of either GOH or GH need to be performed.   
Further structural dynamic analysis of the mPGES-1 crystal structure from 2013 as well as site-directed 
mutagenesis revealed that Ser-127 is not necessary for catalysis, but an interaction between Asp-49 and 
Arg-126 is crucial for enzymatic activity (126). Catalysis is proposed to be mediated through stabilization 
of the thiolate of GSH by Arg-126 and a crystallographic water to function as a proton shuttle to transfer 
the proton from the thiol of GSH to protonate the oxygen of carbon-11 on the substrate cyclopentane ring 
(126). Additional mutagenesis studies of mPGES-1 also confirmed that Ser-127 does not function to 
activate the thiolate of GSH for catalysis, yet mutation of either Asp-49 or Arg-126 residues is detrimental 
to enzyme activity (127).  
 
Conclusions 
 Although a high-resolution crystal structure of mPGES-1 was solved, its catalytic mechanism was 
still not completely elucidated. In order to develop better therapeutic inhibitors, a further understanding of 
the enzyme’s mechanistic properties is needed. By synthesizing GSH analogues, enzyme activity was 
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shown to be completely dependent on the GSH thiolate to exert a nucleophilic attack on the PGH2 substrate. 
Furthermore, site-directed mutagenesis studies completed herein and by labs at the Karolinska Institutet 
determined that thiolate activation was mediated by a crucial interaction between the Asp-49 and Arg-126 
residues as well as a water molecule in the enzyme active site. Stopped-flow spectroscopic studies were 
insufficient to observe the transient loss of the thiolate in the active site in the presence of enzyme inhibitors. 
The physical observation of the thiolate could further verify the enzymatic mechanism and potentially 
identify rate-limiting steps in catalysis. These studies are valuable for future kinetic and inhibitory studies 
of the mPGES-1 enzyme. 
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CHAPTER VII 
 
CONCLUSIONS 
 
Discussion 
 Inflammation is a biological process that protects an organism from chemical or physical injury. 
Activated immune cells release a plethora of reactive chemical species in the affected area to ultimately 
repair tissue damage and resolve the initial causative agent of injury. The acute inflammation typically lasts 
for a short time period but if not resolved, can evolve to a chronic state. The continuous generation of 
reactive chemical mediators can damage not only the affected site of injury, but cellular macromolecules 
from healthy tissue including proteins, lipids, carbohydrates, and nucleic acids. Metabolites of PUFAs are 
potent lipid mediators that function as autocrine or paracrine signaling molecules to regulate many 
processes in the inflammatory pathway. AA is hydrolyzed from the membrane bilayer of cells and 
subsequently metabolized to various classes of eicosanoids that have diverse functions including PGs that 
are primarily pro-inflammatory compounds. The increased production of PGE2 arises from the induced 
expression of the enzymes COX-2 and mPGES-1 which are co-localized in the ER lumen and perinuclear 
region of the cell. COX-2 is inhibited by many NSAIDs which decreases the production of multiple PGs 
that regulate cardiovascular and gastrointestinal processes. mPGES-1 has more recently become a 
therapeutic target for the selective inhibition of PGE2 production, but no inhibitor has yet reached the 
market. 
 The studies in this dissertation investigated the molecular properties of both COX-2 and mPGES-
1. Although many NSAIDs have been developed for COX-2 inhibition, there is still much unknown about 
how they inhibit enzyme activity. Different classes of NSAIDs bind to the COX-2 active site in various 
orientations and exhibit distinct inhibitory kinetics. Some NSAIDs are substrate-selective, in that they are 
more potent for inhibiting the oxygenation of substrates over others. One inhibitor may be substrate-
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selective, whereas another inhibitor from the same class may not be. Although they bind to the enzyme in 
a similar orientation, their molecular basis for substrate selectivity is elusive. 
 mPGES-1 was discovered in the late 1990s by Bengt Samuelsson and collaborators. Since that 
time, the structural and functional properties of the enzyme have been investigated and enzyme inhibitors 
have also been developed. Unfortunately, species differences between the human and rat enzyme isoforms 
and the lipophilic properties of inhibitors have made subsequent in vivo testing challenging. In 2013, a high-
resolution crystal structure was solved of the human mPGES-1 enzyme and a chemical mechanism of 
substrate isomerization was proposed. Unfortunately, no mutagenesis studies were completed and did not 
further support the structural data. The studies herein were completed to further elucidate the chemical 
mechanism of mPGES-1, eventually leading to the design and development of more efficacious inhibitors 
for therapeutic treatment of inflammation. 
 
Molecular Basis of Cyclooxygenase-2 Inhibition by Ibuprofen and Mefenamic Acid 
 The experiments completed here sought to determine the molecular mechanisms of substrate-
selective inhibition of COX-2 by the inhibitors of ibuprofen and mefenamic acid. It is hypothesized that 
substrate-selective inhibitors potently inhibit 2-AG oxygenation by binding in the allosteric subunit of 
COX-2. To inhibit AA oxygenation, a higher concentration of the inhibitor must also bind in the catalytic 
subunit. For ibuprofen inhibition, an apparent dependence on time-dependence was observed for AA 
oxygenation. This result was unexpected as ibuprofen typically rapidly binds to the enzyme and forms a 
weak inhibitor-enzyme complex. Another observation from the experiments completed here was the greater 
effect of peroxide tone on mefenamic acid inhibition of AA and 2-AG oxygenation. In contrast to ibuprofen, 
mefenamic acid is more potent in the absence of a peroxide activator, indicating that the interaction of the 
inhibitor and the catalytic Tyr-385 residue is likely affected. Mefenamic acid can also act as a reducing co-
substrate to reduce the heme, essentially resetting the enzyme to its resting state. Therefore, 2-AG 
oxygenation is more dependent on the presence of peroxide whether or not the inhibitor is preincubated 
with the enzyme. For AA oxygenation, however, a striking difference was observed for peroxide 
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dependence and whether or not mefenamic acid was preincubated with the enzyme. This effect could be 
due to the formation of a low-affinity complex that is not affected by enzyme activation, but a preincubation 
period could form a tighter complex that is more dependent on enzyme activation by peroxide. 
 
Dual Cyclooxygenase-Fatty Acid Amide Hydrolase Inhibitor Exploits Novel Binding Interactions in the 
Cyclooxygenase Active Site 
 
 NSAIDs effectively inhibit the COX enzymes, thus reducing pain and inflammation. However, the 
drugs exhibit cardiovascular and gastrointestinal side effects. ARN2508 is a dual inhibitor of the COX 
enzymes as well as FAAH, thus reducing the production of PGs while concomitantly increasing the 
intracellular concentration of the endocannabinoid AEA. The inhibitor exhibits high potency, target 
selectivity, and decreased gastrointestinal toxicity in mouse models, presumably due to its ability to increase 
levels of AEA and other fatty acyl ethanolamides (FAEs). Herein, the mechanism of COX inhibition by 
ARN2508 was investigated. A 2.27 Å resolution X-ray crystal structure of the COX-2•(S)-ARN2508 
complex reveals that ARN2508 adopts a binding pose similar to that of its parent NSAID flurbiprofen. 
However, ARN2508’s alkyl tail is inserted deep into the top channel, an active site region not exploited by 
any previously reported NSAID. As for flurbiprofen, ARN2508’s potency is highly dependent on the 
configuration of the a-methyl group. Thus, (S)-ARN2508 is more potent than (R)-ARN2508 for inhibition 
of AA oxygenation by both COXs and 2-AG oxygenation by COX-2. Also, similarly to (R)-flurbiprofen, 
(R)-ARN2508 exhibits substrate-selectivity for inhibition of 2-AG oxygenation. Site-directed mutagenesis 
confirms the importance of insertion of the alkyl tail into the top channel for (S)-ARN2508’s potency and 
suggests a role for Ser-530 as a determinant of the inhibitor’s slow rate of inhibition compared to that of 
(S)-flurbiprofen. The Gly-533 residue at the COX upper channel terminus also affects the binding of the w-
tail of ARN2508. Mutating Gly to a bulkier hydrophobic residue slows binding of the inhibitor in the active 
site. 
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Efforts Toward Investigating the Structural Dynamics of Cyclooxygenase-2 With Cryo-Electron 
Microscopy 
 
 Numerous X-ray crystal structures of COX-2 in complex with substrates and inhibitors have been 
solved. The structural data of these compounds in the enzyme active site has provided valuable insights 
into the molecular mechanisms of enzyme. However, X-ray crystallography is limited as a biophysical 
technique as it does not reveal information about enzyme molecular dynamics in the presence of a ligand. 
COX-2 functions as a heterodimer and the binding of one molecule in the allosteric subunit can affect the 
binding of a second substrate or inhibitor in the catalytic subunit. Based on limited information from X-ray 
crystallography, partial occupancy of an NSAID in one subunit reveals a change in the conformation of 
peptides within a loop region of the enzyme dimer interface(65). COX-2 heterodimers with one subunit 
containing a Tyr-385-Phe mutation display similar kinetic parameters as the COX-2 heterodimer with two 
native subunits. In fact, the heme cofactor binds with even higher affinity to the native subunit in the 
presence of the Tyr-385-Phe mutant subunit (62). Multiple amino acid residues form interactions at the 
dimer interface of the enzyme and most likely affect the cross-talk between each subunit. However, 
conformational differences of many of these residues has not been observed by biophysical experiments. 
Here, recombinant COX-2 was reconstituted into membrane mimetics, or nanodiscs, for observation using 
EM. COX-2 nanodiscs were purified with IMAC and size-exclusion chromatography. The nanodiscs 
complexes were initially analyzed using negative stain EM. Cryo-EM was also utilized to investigate the 
structure of the nanodisc complexes. From the acquisition of multiple 2D class averages from the nanodisc 
particles and the atomic structure of AA bound to the COX-2 active site (PDB: 3HS5), a 3D model of the 
COX-2 nanodisc complex was generated for refinement. Although electron density was clearly observed 
for the enzyme homodimer, electron density for the nanodisc bilayer could not be observed, possibly due 
to increased molecular dynamics. 
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Elucidation of the Chemical Mechanism of Human Inducible Microsomal Prostaglandin E2 Synthase 1 
 Based on structural data, the isomerization of PGH2 to PGE2 by mPGES-1 was proposed to be 
initiated by the thiolate of GSH. It was hypothesized that Ser-127 was essential for catalysis by functioning 
as a hydrogen bond donor and stabilizing the thiolate. The studies presented here sought to investigate the 
role of Ser-127 in the chemical mechanism of mPGES-1. Site-directed mutagenesis was utilized to 
determine if Ser-127 was crucial for catalysis. The mutation of Ser-127 to Ala revealed similar enzymatic 
activity to the wild-type enzyme. However, mutation of Ser-127 to Cys reduced enzymatic activity. The 
Ala residue would be unable to act as a hydrogen bond donor to stabilize the thiolate, thus another residue 
in the active site is responsible for its activation. A Cys in the active site most likely reduces activity due to 
the presence of an additional electron shell that might affect the rate of substrate entrance into or product 
exit from the active site cavity. GSO3- is an inhibitor of mPGES-1 and was purified with the Ser-127-Cys 
to determine if the Cys residue could function as a nucleophile to initiate substrate isomerization. However, 
the mutant enzyme had comparable isomerization to that of the spontaneous reaction, indicating that Cys 
can not initiate catalysis. To further assess the role of the GSH thiolate, GSH analogues were synthesized 
and purified with mPGES-1. The oxygen analogue (GOH) and desthio analogue (GH) were unable to 
catalyze substrate isomerization, confirming the thiolate of GSH is essential and must be activated by a 
residue other than Ser-127. Additional collaborative studies with labs at the Karolinska Institutet revealed 
that two additional residues in the active site, Asp-49 and Arg-126, are crucial for activity. With mutations 
of the two residues, it was observed that substrate isomerization to PGE2 was inhibited but the enzyme 
retained reductase activity, producing PGF2a. Further molecular refinement of the crystal structure also 
revealed a water molecule in the active site can function to transfer a proton from GSH to the oxygen of 
carbon-11 of PGH2 (126,127).  
 
Future Studies 
 Although the studies presented here reveal additional information about the mechanisms and 
inhibition of both COX-2 and mPGES-1, many experiments will need to be completed in the future to 
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further advance the field of therapeutic treatment of inflammation. Further understanding the heterodimeric 
properties and substrate-selective inhibition by particular NSAIDs, including ibuprofen and mefenamic 
acid, is critical for developing more effective drugs with fewer side effects. Ibuprofen and mefenamic acid 
can be used in additional experiments for further assessing their dependence on a preincubation period and 
peroxide activation. Although the fixed time point mass spectrometry analysis presented here is an accurate 
method for minimizing substrate turnover and enzyme self-inactivation, longer reaction time points could 
provide additional information regarding inhibitor properties under various experimental parameters. A 
time course experiment with one concentration of mefenamic acid was completed here but completing a 
similar experiment with ibuprofen would be beneficial. Additional inhibition assays could be performed 
with COX-2 reconstituted into nanodiscs to assess if a more native-like environment could possibly affect 
inhibitory kinetics relative to a detergent-solubilized solution. Another valuable experiment to complete 
would be to assess inhibition kinetics in the presence of both AA and 2-AG substrates in the same reaction 
mixture. Since one substrate can affect the oxygenation of the other substrate, the addition of a substrate-
selective inhibitors like ibuprofen or mefenamic acid could provide further information about the allosteric 
behavior of COX-2.  
 Additional studies with ARN2508 will also be valuable for further understanding the molecular 
and structural mechanisms of COX-2. Here, the (S)-enantiomer of the inhibitor was more potent for 
inhibition of both AA and 2-AG. However, the (R)-enantiomer was substrate-selective for 2-AG 
oxygenation. The crystal structure of wild-type COX-2 in complex with (S)-ARN2508 was solved, but 
diffraction quality crystals of wild-type COX-2 in complex with (R)-ARN2508 were not obtained. The 
crystal structure of its parent compound, (R)-flurbiprofen, in complex with COX-2 was previously solved 
and revealed that a conformational change of Tyr-355 at the constriction site allowed the (R)-enantiomer to 
bind in the active site (89). Therefore, it is likely a crystal structure of COX-2•(R)-ARN2508 can eventually 
be solved following optimization of crystallization conditions. In addition to the crystallization of wild-type 
COX-2•(R)-ARN2508, a crystal structure of S530A COX-2 or S530T COX-2 in complex with (S)-
ARN2508 would provide further speculation about how Ser-530 dictates binding of the inhibitor in the 
 112 
enzyme active site. Additional inhibition kinetics could also be completed with the addition of PPHP to 
determine if peroxide tone could exhibit an effect on the substrate-selectivity of (R)-ARN2508.  
 The initial structural investigations of COX-2 nanodiscs using EM provided a good starting point 
for further understanding the dynamics confirmations of the dimer interface. Obviously, additional EM data 
will need to be collected to obtain near atomic resolution of the complex. The initial nanodisc preparations 
indicated that particles can certainly be analyzed, but experimental parameters for the electron microscope 
and molecular refinement will need to be optimized for producing sufficient structural data. Various 
nanodisc complexes can also be formed using variants of the MSP to either increase or decrease the 
diameter of the nanodisc for the purpose of forming a more stable complex. In addition to incorporating 
POPC phospholipids, other phospholipids like PE, PI, and/or PS could be incorporated in various molecular 
ratios to more closely mimic the native membrane bilayer environment. Substrates and inhibitors can also 
be incubated with the COX-2 nanodisc complexes and analyzed with EM to determine if there could be 
conformational change at the dimer interface of the two enzyme subunits. Enzyme with mutations of 
residues at the interface could also be expressed and purified to determine if any conformational changes 
occur. 
 The chemical mechanism of mPGES-1 is now better understood based on mutagenesis studies and 
structural refinement. For future experiments, full enzyme kinetics need to be completed for the mutant 
enzymes to determine differences in substrate binding affinity and turnover compared to the wild-type 
enzyme. Although the Ser-127-Cys mutant was shown to have decreased enzyme activity, it will also be 
necessary to complete full enzyme kinetics in comparison to the wild-type enzyme. Comparing enzyme 
kinetics of Ser-127-Cys mPGES-1 to wild-type enzyme as well as the Ser-127-Ala will make it possible to 
better understand its mechanism of decreased substrate isomerization. HDX-MS might also be useful to 
determine if the presence of the Cys residue in the active site causes conformational changes of specific 
peptides. Since the sulfonate of GSO3- caused changes in solvent accessibility, it is possible that the larger 
thiol of Cys compared to the hydroxyl of the native Ser residue. Completing full kinetic analyses for these 
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mutants will further aid the development of more potent inhibitors of the enzyme. However, extensive work 
will need to be completed to make these inhibitors efficacious for in vivo inhibition. 
 Future experiments integrating COX-2 and mPGES-1 into a single nanodisc complex would be 
useful for understanding their molecular interactions. Kinetic analysis of the COX-2•mPGES-1 nanodisc 
complex would be useful for investigating substrate turnover and product release in a more native-like lipid 
environment. 
 
Concluding Remarks 
 Inflammation can lead to the progression of numerous debilitating diseases including cancers, 
neurodegeneration, arthritis, among others. For many years, inflammatory symptoms were treated with 
natural sources like willow bark. In 1828, the active anti-inflammatory compound of the bark, salicin, was 
isolated. Eventually, acetylsalicyclic acid, or aspirin, was marketed in 1899 but its mechanism of action 
remained unknown for many years. Further studies in the 1960s and 1970s determined that eicosanoids are 
potent lipid mediators that regulate inflammatory processes and their production could be inhibited by the 
action of NSAIDs. These drugs have been very beneficial for the treatment of inflammation and one of their 
molecular targets, COX-2, has been extensively studied. In the late 1990s, mPGES-1 was discovered and 
proposed as a potential therapeutic target for the more selective treatment of inflammation with fewer side 
effects. It is my hope that the studies completed in this dissertation have contributed to the progress of 
understanding these enzymes involved in the inflammatory pathway for the ultimate purpose of developing 
more effective treatments in the future.  
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